⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

HCC is a cancer that grows in the liver, almost always in the setting of chronic liver disease. Hepatitis B, hepatitis C, alcohol-related liver disease, and non-alcoholic steatohepatitis (NASH/MASLD) are the most common underlying causes. Treating the underlying liver disease is essential alongside treating the cancer.
Both the tumor and the liver must be assessed. Unlike most cancers, HCC treatment depends on two things: the cancer stage and how well the remaining liver works. A treatment that cures the tumor but destroys the liver is not a good treatment.
Immunotherapy has transformed advanced HCC since 2020. The combination of atezolizumab + bevacizumab (IMbrave150) replaced sorafenib as the standard first-line treatment, roughly doubling response rates. Tremelimumab + durvalumab (HIMALAYA) is now an alternative first-line option.
If your tumor is small and your liver is healthy enough, cure is possible. Surgical resection, liver transplant, and ablation can all be curative for early-stage HCC. Transplant cures both the cancer and the underlying liver disease.
Locoregional therapies are a cornerstone of HCC treatment. Transarterial chemoembolization (TACE), radioembolization (Y-90), and ablation treat tumors directly without major surgery. Many patients receive these as primary treatment or as a bridge to transplant.
Liver transplant can cure both the cancer and cirrhosis. Patients who meet transplant criteria (generally the Milan criteria) have excellent long-term outcomes. Get evaluated for transplant early if there is any chance you might be eligible.
AFP (alpha-fetoprotein) is an important blood marker. AFP levels help with diagnosis, prognosis, and monitoring treatment response. An AFP above 400 ng/mL has specific treatment implications, including eligibility for ramucirumab in the second-line setting.
Get to a multidisciplinary liver tumor board. HCC treatment decisions are complex and require input from hepatologists, surgeons, transplant specialists, interventional radiologists, medical oncologists, and radiation oncologists. A multidisciplinary tumor board is the single most important step.

▼ Collapse

Understanding Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for approximately 75–85% of all liver cancers. It develops in the hepatocytes — the main functional cells of the liver. In nearly all cases, HCC arises in a liver that is already damaged by chronic disease, most commonly cirrhosis.

The liver has remarkable regenerative capacity, but chronic damage from hepatitis viruses, alcohol, or metabolic disease leads to progressive scarring (fibrosis), which eventually becomes cirrhosis. In a cirrhotic liver, the ongoing cycles of cell death and regeneration create conditions where cancer-causing mutations are more likely to occur.

Approximately 42,000 new cases of liver and intrahepatic bile duct cancer per year in the United States, the majority being HCC
Approximately 30,000 deaths per year in the United States
5th most common cancer worldwide and the 3rd leading cause of cancer-related death globally
Incidence is rising in the United States and Europe, largely driven by NASH/MASLD and the aging hepatitis C cohort
Approximately 3 times more common in men than women
Incidence varies dramatically worldwide: highest in East Asia and sub-Saharan Africa (hepatitis B endemic regions), lower in Western countries

Hepatitis B virus (HBV): The leading cause worldwide, especially in Asia and Africa. HBV can cause HCC even without cirrhosis. Vaccination prevents HBV and therefore prevents HCC.
Hepatitis C virus (HCV): The most common cause in the US and Europe. Successful antiviral treatment (cure) reduces but does not eliminate HCC risk; surveillance must continue.
Alcohol-related liver disease: Chronic heavy alcohol use causes cirrhosis, which leads to HCC. Risk increases with the amount and duration of alcohol use.
Non-alcoholic steatohepatitis (NASH/MASLD): The fastest-growing cause of HCC in the United States. Associated with obesity, type 2 diabetes, and metabolic syndrome. Notably, NASH-related HCC can develop even without cirrhosis in some patients.
Aflatoxin exposure: A carcinogen produced by fungi that contaminate grain and nuts in tropical regions. A major risk factor in sub-Saharan Africa and parts of Asia.
Hereditary hemochromatosis: Iron overload disorder that damages the liver.
Other: Primary biliary cholangitis, alpha-1 antitrypsin deficiency, autoimmune hepatitis.

The most important concept in this guide: HCC is two diseases in one — a cancer and a liver disease. Every treatment decision must weigh the tumor against the liver. The best cancer treatment is worthless if it causes liver failure. This is why a multidisciplinary team is essential, and why staging systems for HCC incorporate liver function, unlike staging for most other cancers.

Understanding how HCC develops in your specific context helps explain some of the monitoring and treatment decisions your team will make. The vast majority of HCC arises in a liver that has been damaged over years or decades. Repeated cycles of injury, inflammation, and repair create an environment where cells accumulate genetic mutations, and where growth-promoting signals are amplified.

The cirrhotic microenvironment: Cirrhosis (the end-stage scarring of the liver from any cause) creates structural changes that promote cancer. The normal liver architecture, which allows efficient blood flow and cell-to-cell signaling, is replaced by nodules of regenerating cells surrounded by fibrous bands. These regenerating cells are proliferating rapidly and are therefore more vulnerable to mutations. The reduced immune surveillance in a damaged liver allows early cancer cells to escape detection.

Key risk pathways by etiology:

Hepatitis B virus (HBV): HBV DNA can integrate directly into the human genome, disrupting tumor suppressor genes and activating oncogenes. This integration can occur early in HBV infection, before cirrhosis develops — which is why HBV-positive individuals can develop HCC without cirrhosis, unlike most other HCC risk factors.
Hepatitis C virus (HCV): HCV does not integrate into the genome. Instead, it drives HCC through chronic inflammation, oxidative stress, and immune dysregulation. HCV-related HCC almost always arises in the setting of advanced fibrosis (F3) or cirrhosis (F4). Curing HCV with direct-acting antivirals substantially reduces but does not eliminate HCC risk in patients who already have cirrhosis — the cirrhotic architecture persists and maintains elevated risk.
NASH/NAFLD (non-alcoholic fatty liver disease): The metabolic syndrome — obesity, type 2 diabetes, hypertension, dyslipidemia — drives NAFLD-associated HCC through lipotoxicity, insulin resistance, gut microbiome changes, and chronic low-grade inflammation. Importantly, NAFLD-HCC can occasionally arise in non-cirrhotic liver, particularly in patients with metabolic syndrome and advanced fibrosis (F3). This makes surveillance more complex, because the current surveillance recommendations are designed primarily around cirrhosis.
Alcohol-related liver disease: Chronic heavy alcohol use causes hepatitis, steatosis, and ultimately cirrhosis. The HCC risk is proportional to alcohol intake and duration; there is no absolutely safe level of alcohol consumption once cirrhosis is established. Complete alcohol abstinence reduces disease progression and, in some cases, allows compensated cirrhosis to improve in liver function over time.
Aflatoxin: In sub-Saharan Africa and parts of Asia, contamination of crops (particularly corn and peanuts) with aflatoxin B1 (a mycotoxin from the mold Aspergillus) is a major HCC risk factor, operating through a specific TP53 mutation. Aflatoxin-related HCC represents a significant proportion of global HCC burden even in the absence of other hepatic risk factors.

The two-hit model for HCC: Most HCC does not arise from a single event but from an accumulation of genetic hits over time. The cirrhotic (or chronically inflamed) liver provides the first hit: an environment of elevated oxidative stress, rapid cell turnover, and impaired tumor suppression. Individual cellular mutations — in TP53, CTNNB1 (beta-catenin), TERT promoter, and others — represent the second hit that drives transformation. This is why addressing the underlying liver disease (treating HBV/HCV, stopping alcohol, managing metabolic syndrome) is important not only for your liver health but for your ongoing HCC risk, even after HCC has been diagnosed and treated.

Key Breakthroughs in HCC

HCC treatment has been transformed since 2020, ending a decade-long period when sorafenib was the only effective systemic therapy. Here are the most important advances:

FDA-APPROVED The IMbrave150 trial established atezolizumab (an immune checkpoint inhibitor targeting PD-L1) combined with bevacizumab (an anti-VEGF antibody) as the new standard first-line treatment for unresectable HCC. This combination improved overall survival and progression-free survival compared to sorafenib, with an overall response rate of approximately 30% versus 11% with sorafenib. It was the first regimen in over a decade to outperform sorafenib and ended its 13-year reign as the only systemic option.

FDA-APPROVED The HIMALAYA trial showed that the STRIDE regimen (a single priming dose of tremelimumab, an anti-CTLA-4 antibody, followed by durvalumab, an anti-PD-L1 antibody) improved overall survival compared to sorafenib. This provides an important alternative for patients who cannot receive bevacizumab (e.g., those with high risk of variceal bleeding, recent gastrointestinal bleeding, or uncontrolled hypertension).

NEGATIVE RESULT The IMbrave050 trial initially reported that atezolizumab + bevacizumab given after curative-intent surgery or ablation reduced the risk of recurrence compared to active surveillance. However, updated analysis with longer follow-up (published 2024/2026) showed that the initial recurrence-free survival benefit was not sustained. The investigators concluded that the benefit-risk profile does not support atezolizumab plus bevacizumab as adjuvant therapy for HCC. This regimen should not be considered a standard adjuvant option.

FDA-APPROVED The REFLECT trial showed lenvatinib was non-inferior to sorafenib in overall survival, with higher response rates (24% vs 9%) and improved progression-free survival. Lenvatinib remains an option for patients who cannot receive immunotherapy, such as those with autoimmune conditions or prior organ transplant.

EMERGING Multiple trials are exploring the combination of transarterial chemoembolization (TACE) with immune checkpoint inhibitors or targeted therapies. The EMERALD-1 trial (TACE + durvalumab + bevacizumab), LEAP-012 (TACE + lenvatinib + pembrolizumab), and TACE-3 are among the key studies. Early results suggest that adding systemic therapy to TACE may improve outcomes for intermediate-stage HCC, potentially changing the treatment paradigm for this large patient group.

Diagnosis: How HCC Is Found and Confirmed

HCC is unique among solid tumors because it can often be diagnosed by imaging alone, without a biopsy. In a patient with cirrhosis and a liver mass that shows a specific pattern on contrast-enhanced imaging, the diagnosis can be made radiologically.

The Liver Imaging Reporting and Data System (LI-RADS) provides a standardized way to classify liver observations on CT or MRI in patients at risk for HCC:

LI-RADS 5 (definitely HCC): A lesion ≥10 mm showing arterial phase hyperenhancement AND washout AND enhancing capsule on contrast-enhanced CT or MRI. This is diagnostic of HCC — no biopsy needed.
LI-RADS 4 (probably HCC): High suspicion but not all classic features present. May require short-interval follow-up or biopsy.
LI-RADS 3 (intermediate): Some concerning features. Follow-up in 3–6 months recommended.
LI-RADS M (malignant, not HCC-specific): May represent intrahepatic cholangiocarcinoma or combined tumors. Biopsy typically needed.

Key imaging modalities: Contrast-enhanced multiphasic CT or MRI with liver-specific contrast agents (gadoxetate/Eovist) are the standard for HCC diagnosis and staging.

Liver mass in a non-cirrhotic liver (imaging criteria validated only for cirrhotic livers)
Imaging features are atypical or indeterminate (LI-RADS 3 or LI-RADS M)
Suspicion for a different type of liver cancer (e.g., cholangiocarcinoma or combined HCC-cholangiocarcinoma)
Before starting systemic therapy when histological confirmation is required by clinical trial or institutional protocol

Biopsy risks: In cirrhotic livers, biopsy carries a small risk of bleeding and an extremely small risk of needle-track tumor seeding. These risks are why imaging diagnosis is preferred when criteria are met.

Alpha-fetoprotein (AFP) is the most widely used blood marker for HCC:

AFP >400 ng/mL in the setting of a liver mass is highly suggestive of HCC
AFP >1,000 ng/mL is associated with more aggressive disease and poorer prognosis
AFP is NOT reliable as a standalone screening test — approximately 40% of HCC tumors produce little or no AFP. An AFP in the normal range does not rule out HCC.
AFP-L3 fraction and des-gamma-carboxyprothrombin (DCP/PIVKA-II) are additional biomarkers used in some centers, particularly in Japan and Asia
AFP >400 ng/mL at progression on or after sorafenib/lenvatinib qualifies a patient for second-line ramucirumab (REACH-2 trial)

Staging — How HCC Is Classified

HCC uses multiple staging systems because the cancer and the liver must be assessed together. The most widely used staging system in Western countries is the Barcelona Clinic Liver Cancer (BCLC) system, which incorporates tumor burden, liver function, and the patient’s overall condition.

BCLC Stage	Tumor Characteristics	Liver Function & Status	Recommended Treatment
0 (Very Early)	Single nodule ≤2 cm, no vascular invasion	Child-Pugh A, ECOG 0	Resection or ablation — curative intent
A (Early)	Single nodule or up to 3 nodules ≤3 cm each, no vascular invasion	Child-Pugh A–B, ECOG 0	Resection, transplant, or ablation — curative intent
B (Intermediate)	Multinodular, large or multifocal, no vascular invasion or extrahepatic spread	Child-Pugh A–B, ECOG 0	TACE (with potential systemic combination)
C (Advanced)	Vascular invasion (portal vein thrombosis) and/or extrahepatic spread	Child-Pugh A–B, ECOG 1–2	Systemic therapy (atezolizumab+bevacizumab or STRIDE)
D (End-Stage)	Any	Child-Pugh C or ECOG 3–4	Best supportive care

Important: Staging is not rigid. Treatment decisions are increasingly individualized. A patient with BCLC B disease may receive systemic therapy if TACE is not feasible, and some patients with BCLC C disease may be considered for locoregional therapy with systemic combination. This is why a multidisciplinary tumor board review is essential.

The period right after diagnosis is overwhelming. These questions will help you gather the information you need to make informed decisions:

About your specific HCC:

What is my BCLC stage, and what does that mean for my treatment options?
How many tumors do I have, and where exactly are they? Are any of them in or near major blood vessels?
Is there any evidence of portal vein involvement (portal vein tumor thrombus) or lymph node or distant spread?
What is my AFP level now, and what will you expect it to do if treatment is working?

About your liver:

What is my Child-Pugh class or ALBI grade? What does this tell you about which treatments I can safely tolerate?
Do I have varices that need to be evaluated before starting systemic therapy?
Is my hepatitis B or C fully under control? Do I need antiviral prophylaxis during cancer treatment?
Am I a candidate for liver transplant? Who specifically is evaluating me for transplant?

About the treatment plan:

Was my case reviewed by a multidisciplinary liver tumor board? If not, can it be?
What is the goal of my recommended treatment — cure, downstaging, or disease control?
Am I a candidate for a clinical trial? Can you refer me to an academic center trial program?
What would need to happen for my cancer to be considered for curative treatment (surgery, ablation, or transplant) if I am currently being treated with palliative intent?

What are the most common side effects of this specific regimen, and which ones require me to call right away vs. which ones I can manage at home?
Is there any pre-treatment I need to complete first (endoscopy for varices, HBV prophylaxis, thyroid baseline)?
How will we know if this treatment is working? When will we do the first scan, and what are we hoping to see?
What happens if this treatment stops working — what is the next line of therapy?
Are there dietary restrictions or medications I should avoid while on this therapy?
What is the cost, and can you connect me with financial counseling or patient assistance programs?

HCC can spread to the lungs, lymph nodes, bones, and adrenal glands. The presence of extrahepatic spread places the cancer in BCLC-C (advanced stage) and generally requires systemic therapy rather than locoregional approaches. If you have been told your cancer has spread outside the liver, these questions are important:

What sites are affected? How many lesions, and what size?
If I have lung metastases: are they causing symptoms? Are they still small enough that systemic therapy alone is the right approach, or does radiation to specific lung lesions have a role?
If I have bone metastases: Am I at risk for fracture? Should I be referred to radiation oncology for palliative radiotherapy to painful or structurally threatening bone lesions? Should I be receiving bone-protective therapy (zoledronic acid or denosumab)?
If the cancer is in lymph nodes near the liver: Does this change my eligibility for liver transplant? How does this affect my BCLC stage and treatment options?
Is there a role for stereotactic body radiation therapy (SBRT) for isolated metastases while I continue systemic therapy?
How often will imaging be repeated to assess all disease sites, including the extrahepatic ones?

Liver Function Assessment — Child-Pugh and ALBI

Because most HCC patients have underlying liver disease, assessing liver function is critical before any treatment. Two main scoring systems are used:

The Child-Pugh score (A, B, or C) rates liver function based on five factors: bilirubin, albumin, INR (clotting time), ascites, and encephalopathy. Each factor is scored 1–3, with a total score of 5–6 = Class A (well-compensated), 7–9 = Class B (significant impairment), 10–15 = Class C (decompensated).

Child-Pugh A: Most treatment options are available, including surgery, TACE, and systemic therapy.
Child-Pugh B: Treatment options are more limited. Close monitoring for liver decompensation is essential. Some systemic therapies may still be feasible (B7 is very different from B9).
Child-Pugh C: The liver is severely compromised. Most cancer treatments carry high risk of worsening liver failure. Transplant evaluation or best supportive care are the primary options.

The albumin-bilirubin (ALBI) grade is a newer, simpler assessment using only serum albumin and bilirubin levels. It subdivides Child-Pugh A patients more precisely and is increasingly used in clinical trials. ALBI grade 1 patients have better outcomes than ALBI grade 2, even within Child-Pugh A.

What is my BCLC stage, and what does it mean for my treatment options?
What is my Child-Pugh score? Is my liver function well enough to tolerate the treatments you are recommending?
What is the cause of my underlying liver disease, and is it being treated?
What is my AFP level, and what does it mean?
Is there any vascular invasion or spread outside the liver?
Am I a candidate for liver transplant?
Has my case been reviewed by a multidisciplinary liver tumor board?
Should I have a liver biopsy, or can the diagnosis be made by imaging?

Surgery & Ablation (Curative Treatments)

For patients with early-stage HCC and adequate liver function, curative treatments can offer the possibility of long-term disease-free survival. The three curative approaches are surgical resection, liver transplant, and ablation.

Surgical removal of the tumor along with a margin of normal liver tissue is the preferred treatment for patients with a single tumor and well-preserved liver function (Child-Pugh A, no portal hypertension). Key considerations:

The remaining liver must be large enough and healthy enough to sustain life after surgery (future liver remnant assessment)
Minimally invasive (laparoscopic/robotic) resection is increasingly used and may reduce recovery time
5-year survival after resection for early-stage HCC is approximately 60–80%
Recurrence is the major challenge: approximately 50–70% of patients develop recurrence within 5 years, either in the remaining liver or as new primary tumors arising from the underlying cirrhosis
As of 2026, no adjuvant therapy has demonstrated a sustained benefit in HCC. The IMbrave050 trial (atezolizumab + bevacizumab) initially showed promise but updated data did not confirm a durable recurrence-free survival benefit. Clinical trials of adjuvant approaches are ongoing.

Ablation uses heat (radiofrequency ablation or microwave ablation) or extreme cold (cryoablation) to destroy small tumors in place, without removing them. It is an alternative to surgery for patients with tumors ≤3 cm and is sometimes used for tumors up to 5 cm.

Can be performed percutaneously (through the skin), laparoscopically, or during open surgery
Recovery time is shorter than surgical resection
Best results for tumors ≤2 cm, where ablation achieves outcomes comparable to surgical resection
Local recurrence rates increase with larger tumor size
Can be used as a bridge to liver transplant to prevent tumor progression while waiting for a donor

After curative treatment, surveillance is essential. Because recurrence rates are high, patients need regular follow-up with imaging (typically multiphasic CT or MRI every 3–6 months for the first 2 years, then every 6 months) and AFP monitoring. No adjuvant therapy has yet demonstrated sustained benefit in HCC; ask your oncologist about clinical trials of adjuvant approaches.

Locoregional Therapies

Locoregional therapies treat HCC by targeting the tumor directly through the blood supply or by applying radiation internally. These treatments are the standard of care for intermediate-stage (BCLC B) HCC and are also used as a bridge to transplant or as downstaging approaches.

TACE delivers chemotherapy directly into the artery feeding the tumor, then blocks (embolizes) that artery, trapping the drug in the tumor and cutting off its blood supply. Two main types:

Conventional TACE (cTACE): Lipiodol mixed with chemotherapy (doxorubicin or cisplatin) followed by embolic particles
Drug-eluting bead TACE (DEB-TACE): Beads loaded with doxorubicin that release the drug slowly. May cause fewer systemic side effects.

TACE can be repeated multiple times. It is not recommended for patients with portal vein thrombosis (main branch), decompensated liver disease (Child-Pugh C), or extensive tumor burden.

Post-embolization syndrome (fever, abdominal pain, nausea) is common for 3–7 days after TACE and is typically manageable with supportive care.

Radioembolization delivers microscopic radioactive glass or resin beads (yttrium-90) directly into the tumor’s blood supply. The beads lodge in the tumor’s microvasculature and deliver high-dose radiation from the inside.

Can be used in patients with portal vein thrombosis (unlike TACE)
May cause less liver damage than TACE in some settings
Used for both intermediate and advanced HCC
Radiation segmentectomy (targeting a single segment) can achieve ablative doses for small tumors
Requires a planning angiogram (mapping study) 1–2 weeks before treatment to assess shunting to the lungs

SBRT delivers precisely focused, high-dose external radiation to the tumor over 3–5 treatment sessions. It is an alternative when surgery, ablation, and TACE are not feasible.

Can treat tumors near major blood vessels where ablation is risky
Can treat portal vein tumor thrombus
Requires careful dose planning to protect normal liver tissue
Increasingly studied in combination with immunotherapy

Am I a candidate for surgery, ablation, or transplant?
What type of locoregional therapy do you recommend, and why?
How many times can TACE be safely repeated?
Is TACE plus systemic therapy an option for me?
Could Y-90 radioembolization be a better option than TACE for my tumor?
What is the plan if locoregional therapy does not control the tumor?
Are there adjuvant clinical trials I should consider after curative treatment?
Is there a clinical trial combining locoregional and systemic therapy?
What will happen to my liver function after this treatment?

When your team reviews your imaging to see if treatment is working, they use specific criteria to measure response. Understanding what these terms mean in your scan report helps you interpret the news you receive.

mRECIST (modified Response Evaluation Criteria in Solid Tumors) is the standard for HCC because it measures the viable (living) tumor tissue, not just the total tumor size. HCC tumors treated with locoregional therapies (TACE, SIRT) or ablation can die while maintaining their original size — the dead tissue remains as scar. mRECIST specifically measures only the arterially enhancing (living) component:

Complete Response (CR): No remaining arterially enhancing tumor tissue visible. For locoregional treatments, CR means the treated tumor is fully dead (necrotic). For systemic therapy, CR is rare but represents the best possible outcome.
Partial Response (PR): At least 30% reduction in the sum of viable (enhancing) tumor diameters. In HCC, PR during TACE or immunotherapy predicts better long-term outcomes. It does not mean the cancer is gone, but it means the treatment is working.
Stable Disease (SD): Neither enough shrinkage to qualify as PR nor enough growth to qualify as PD. For rapidly growing cancers like HCC, stable disease during systemic therapy is often a meaningful clinical benefit — stopping growth is valuable even without shrinkage.
Progressive Disease (PD): At least 20% increase in viable tumor or any new tumor lesion. PD is the signal to reconsider or change treatment.

Arterial enhancement on CT/MRI: HCC tumors have a characteristic blood supply pattern called arterial enhancement followed by portal washout — the tumor lights up brightly on early contrast images (arterial phase) and then "washes out" to appear darker than surrounding liver on delayed images. After treatment, the goal is to eliminate this enhancement pattern (indicating dead tumor). When your scan says "no residual enhancement" in a treated area, that is a good sign. When it shows "new or persistent enhancement," that indicates living tumor.

When the scan shows improvement but you feel worse: It is common for patients to feel fatigued or unwell during effective treatment. Scan improvement (shrinking viable tumor) while symptoms seem worse is not necessarily a contradiction. The two are on different timescales: tumor shrinkage happens over weeks, while fatigue and side effects can be immediate. Communicate all of your symptoms to your team so they can distinguish treatment side effects from disease-related symptoms, but do not assume a worsening symptom means your cancer is getting worse — rely on your imaging and labs for that assessment.

Systemic Therapy — First-Line

Systemic therapy treats cancer throughout the body using drugs given intravenously or orally. It is the standard of care for advanced HCC (BCLC C) with vascular invasion or extrahepatic spread, and is increasingly used for intermediate-stage disease when locoregional therapy is not feasible or in combination with TACE.

FDA-APPROVED The IMbrave150 trial established atezolizumab + bevacizumab as the preferred first-line systemic therapy for unresectable HCC in patients with Child-Pugh A liver function. Key results:

Median overall survival: 19.2 months vs. 13.4 months with sorafenib (updated data)
Objective response rate: 30% vs. 11% with sorafenib
Quality of life: better maintained compared to sorafenib

Before starting: All patients must undergo an upper endoscopy (EGD) to screen for and treat esophageal varices. Bevacizumab increases bleeding risk, and variceal bleeding can be life-threatening. Varices must be treated before starting therapy.

Who should NOT receive this: Patients with autoimmune conditions requiring immunosuppression, organ transplant recipients (risk of graft rejection), uncontrolled hypertension, recent GI bleeding, or untreated varices.

FDA-APPROVED The HIMALAYA trial showed the STRIDE regimen (single high-dose tremelimumab 300 mg × 1 + durvalumab 1500 mg q4w) improved overall survival versus sorafenib:

Median OS: 16.4 months vs. 13.8 months with sorafenib
3-year OS rate: 30.7% vs. 20.2% with sorafenib

Key advantage: Does not require bevacizumab, so no mandatory pre-treatment endoscopy for varices. Suitable for patients with bleeding risk or cardiovascular contraindications to bevacizumab.

FDA-APPROVED In April 2025, the FDA approved the dual-immunotherapy combination of nivolumab (Opdivo) + ipilimumab (Yervoy) as a first-line option for unresectable or metastatic HCC, based on the CheckMate 9DW trial:

Median overall survival: 23.7 months vs. 20.6 months with lenvatinib or sorafenib
This is a chemotherapy-free, bevacizumab-free regimen — so it does not require pre-treatment endoscopy for varices

Trade-off: Combining two checkpoint inhibitors raises the rate of immune-related side effects (e.g., colitis, hepatitis, endocrine effects) compared with a single checkpoint drug, so it requires close monitoring. As with other checkpoint regimens, it is generally avoided in people with active autoimmune disease or organ transplants.

FDA-APPROVED Tyrosine kinase inhibitors (TKIs) remain important for patients who cannot receive checkpoint immunotherapy:

Sorafenib: The first systemic therapy proven to improve survival in HCC (SHARP trial, 2007). Median OS approximately 10–13 months. Common side effects: hand-foot skin reaction, diarrhea, fatigue, hypertension.
Lenvatinib: Non-inferior to sorafenib in overall survival, with higher response rates (REFLECT trial). Median OS approximately 13.6 months. Common side effects: hypertension, fatigue, diarrhea, appetite loss, weight loss.

When TKIs are preferred over immunotherapy: Autoimmune hepatitis or other active autoimmune conditions; prior solid organ transplant (especially liver transplant recipients); severe portal hypertension with untreatable varices; patient preference.

Second-Line and Beyond

When first-line treatment stops working or is not tolerated, several options exist:

Drug	Setting	Key Trial	Key Result
Cabozantinib	After sorafenib or lenvatinib	CELESTIAL (NCT01908426)	Improved median OS to 10.2 vs. 8.0 months (HR 0.76)
Regorafenib	After sorafenib (must have tolerated sorafenib)	RESORCE (NCT01774344)	Improved median OS to 10.6 vs. 7.8 months (HR 0.63)
Ramucirumab	After sorafenib, AFP ≥400 ng/mL only	REACH-2 (NCT02435433)	Improved median OS to 8.5 vs. 7.3 months (HR 0.71)
Pembrolizumab	After sorafenib (immunotherapy option)	KEYNOTE-224 / KEYNOTE-394 (NCT03062358)	FDA-approved second-line (accelerated approval 2018; confirmed by KEYNOTE-394: improved OS, PFS, and response)
Lenvatinib or Sorafenib	After immunotherapy progression	—	TKIs commonly used after ICI progression; limited prospective data

After immunotherapy progression: The optimal second-line therapy after atezolizumab+bevacizumab or STRIDE is an active area of research. TKIs (sorafenib, lenvatinib, cabozantinib) are commonly used, but prospective trial data in this specific sequence are limited. Clinical trials should be strongly considered.

Am I a candidate for immunotherapy, or do I need a TKI instead? Why?
Have I been screened for esophageal varices before starting bevacizumab?
What side effects should I watch for with immunotherapy (especially liver-related)?
If my treatment stops working, what is the next-line plan?
Is my AFP being monitored, and what does the trend mean?
Should I be on antiviral therapy for hepatitis B or C during cancer treatment?
Are there clinical trials I should consider?
Is my liver function still adequate for this treatment?

Liver Transplant

Liver transplant is the only treatment that can cure both the HCC and the underlying liver disease. For eligible patients, it offers the best long-term outcomes, with 5-year survival rates of 70–80%.

The Milan criteria, established in 1996, remain the most widely used benchmark for transplant eligibility:

A single tumor ≤5 cm, OR
Up to 3 tumors, each ≤3 cm
No vascular invasion
No extrahepatic spread

Patients who meet Milan criteria have a recurrence rate of less than 10–15% after transplant.

Several centers use expanded criteria for transplant eligibility:

UCSF criteria: Single tumor ≤6.5 cm OR 2–3 tumors ≤4.5 cm with total tumor diameter ≤8 cm
Up-to-7 rule: Sum of the largest tumor diameter (cm) + number of tumors ≤7 (without microvascular invasion)
AFP score (French model): Combines tumor number, size, and AFP level to predict post-transplant outcomes

Downstaging: Patients who initially exceed Milan criteria may be treated with locoregional therapy (TACE, Y-90, ablation) to shrink tumors to within Milan criteria. If downstaging is successful and sustained, transplant outcomes are comparable to those who initially met criteria.

Patients listed for transplant often wait months for a donor organ. During this waiting period, locoregional therapy (TACE, Y-90, ablation) is used to prevent tumor progression that might cause the patient to drop off the transplant list. This is called bridging therapy.

A healthy person can donate a portion of their liver to a patient with HCC. The donated portion and the remaining liver both regenerate to near-normal size. Living donor liver transplant (LDLT) eliminates the wait for a deceased donor organ, which is especially important in regions with long transplant waiting times. LDLT is widely practiced in Asia and is growing in the United States.

Critical warning for transplant recipients: Patients who have received a liver transplant and are on immunosuppression should NOT receive immune checkpoint inhibitors (atezolizumab, durvalumab, nivolumab, pembrolizumab). These drugs can cause severe graft rejection. If HCC recurs after transplant, treatment options are limited to TKIs (sorafenib, lenvatinib), locoregional therapy, or clinical trials of agents that do not stimulate the immune system.

Before starting any systemic therapy — hepatitis B screening and prevention: Everyone starting systemic treatment for HCC (immunotherapy, TKIs, or chemotherapy) should be screened for hepatitis B (HBsAg, anti-HBc, anti-HBs). If you have ever been exposed to hepatitis B, your team should start an antiviral medicine (entecavir or tenofovir) before and during treatment to prevent hepatitis B reactivation — a serious, sometimes fatal liver flare that is almost entirely preventable. Active hepatitis B or C should also be treated to protect your liver. Ask your team to confirm your hepatitis status before your first dose.

HCC Surveillance — Who Should Be Screened and How

Most hepatocellular carcinoma can be detected at an earlier, treatable stage if the person at risk is enrolled in a formal surveillance program. The challenge is that early HCC causes no symptoms — a tumor small enough to cure is a tumor too small to feel. Surveillance is the only way to find it.

Who is at high enough risk to warrant surveillance?

American (AASLD) and European (EASL) guidelines are aligned on the populations who benefit:

Cirrhosis from any cause — viral hepatitis (B or C), alcohol, NASH/NAFLD, autoimmune, hemochromatosis, primary biliary cholangitis, and others. Cirrhosis is the single strongest HCC risk factor; approximately 80% of HCC in the United States arises in cirrhotic liver.
Chronic HBV infection without cirrhosis — HBV is unique among HCC risk factors because it can cause HCC even without cirrhosis, via direct viral integration and oncogene activation. Surveillance is recommended for: Asian men with HBV aged 40+, Asian women with HBV aged 50+, HBV carriers with a family history of HCC (any age), African/North American Blacks with HBV (any age, as HCC onset is typically earlier in this population), and any HBV carrier with cirrhosis.
Hepatitis C with advanced fibrosis (F3–F4) — Even after sustained virologic response (SVR, cure) with direct-acting antivirals, the residual HCC risk in HCV-related cirrhosis remains elevated enough to warrant continued surveillance for at least 5–10 years post-cure, and potentially indefinitely in those with established cirrhosis.
Non-alcoholic fatty liver disease (NAFLD) with cirrhosis — NAFLD-related HCC is the fastest-growing indication for surveillance in the United States as obesity and metabolic syndrome prevalence rise. Note: NAFLD-HCC can occasionally arise without full cirrhosis, particularly in men with significant metabolic risk factors — your hepatologist will advise whether surveillance is warranted in your specific case even if a formal cirrhosis diagnosis has not been made.

How surveillance is performed

Abdominal ultrasound every 6 months — the standard recommended modality. It is non-invasive, does not use radiation, and is widely available. Limitations: ultrasound quality depends on operator experience and patient body habitus (obesity, intestinal gas); it can miss small tumors (<1 cm) in some patients, and is particularly limited in obese patients with NAFLD cirrhosis, where the liver echogenicity makes differentiation difficult.
Serum AFP (alpha-fetoprotein) every 6 months — AASLD guidelines designate AFP as optional rather than mandatory, because AFP alone has poor sensitivity (misses roughly 40% of small HCCs) and poor specificity (elevated AFP occurs in hepatitis flares, pregnancy, and other cancers). However, AFP is still widely used in practice, and trend matters as much as a single value: a rising AFP with a new liver lesion is more concerning than a stable elevated AFP with no new finding.
When ultrasound is inadequate: If your ultrasound is consistently technically limited (poor visualization), your hepatologist may recommend alternating with or switching to contrast-enhanced CT or MRI every 6 months. CT uses radiation; MRI avoids radiation and is preferred in younger patients and in those with borderline lesions requiring characterization.
LI-RADS (Liver Imaging Reporting and Data System): When imaging finds a liver observation, radiologists trained in HCC use the LI-RADS scale to categorize it from LR-1 (definitely benign) to LR-5 (definitely HCC). LR-M indicates a probably malignant lesion that doesn’t fit classic HCC features (could be intrahepatic cholangiocarcinoma or other malignancy). LR-5 is diagnostic of HCC without biopsy in at-risk patients — liver biopsy is usually not required.

Questions to Ask at Your Next Surveillance Visit

Am I currently enrolled in a 6-month surveillance program? Who is responsible for ordering and tracking my results?
Was my last ultrasound technically adequate, or were parts of my liver not visible?
What is my AFP trend over the past year? Are you concerned by the trajectory?
If a lesion is found, what is the next step — how quickly would I be seen by the liver tumor board?

Living with Portal Hypertension and HCC

Most people with HCC have liver cirrhosis, which causes portal hypertension — elevated pressure in the portal vein (the main vein bringing blood from the gut and spleen to the liver). Portal hypertension produces a set of complications that require active management alongside your HCC treatment, because they can affect which HCC therapies are safe for you and how well you tolerate them.

Portal hypertension causes blood to be rerouted through collateral veins in the esophagus, stomach, and rectum (hemorrhoids). These veins, called varices, can rupture and bleed rapidly — variceal hemorrhage is a medical emergency with a mortality rate of 15–25% per episode. Your treatment team will want to know your variceal status before starting systemic HCC therapy, because:

Bevacizumab (part of the atezolizumab + bevacizumab regimen) impairs wound healing and can worsen variceal bleeding risk. AASLD and ESMO guidelines require endoscopic screening and treatment of high-risk varices before starting this combination.
TKIs (sorafenib, lenvatinib, cabozantinib) generally do not markedly increase variceal bleeding risk, but their effects on liver function can indirectly affect portal pressure over time.

Variceal prevention and management: Your gastroenterologist or hepatologist may recommend non-selective beta-blockers (propranolol or carvedilol) to reduce portal pressure and prevent first variceal bleed (primary prophylaxis), or endoscopic band ligation (EBL) to directly treat visible high-risk varices. Ask your team what your variceal status is and whether you are on prophylaxis.

Ascites (fluid in the abdominal cavity) affects about 50% of people with cirrhosis within 10 years, and is one of the most common portal hypertension complications you will encounter during HCC treatment. Signs include increased abdominal girth, a feeling of fullness or pressure, shortness of breath when lying flat, and weight gain.

Dietary sodium restriction: 2,000 mg of sodium per day (<5 g table salt). This is the cornerstone of ascites management alongside diuretics. Working with a registered dietitian experienced in liver disease is strongly recommended, as achieving this restriction while maintaining adequate nutrition and palatability requires specific dietary strategies.
Diuretics: Most commonly spironolactone (a potassium-sparing diuretic) alone or combined with furosemide in a ratio that avoids electrolyte imbalance. These are started at low doses and titrated based on your weight and kidney function.
Large-volume paracentesis (LVP): For tense or refractory ascites not responding to diuretics, fluid is drained through a needle placed into the abdomen under ultrasound guidance. This is a same-day procedure, typically done as an outpatient. When more than 5 liters are removed, albumin infusion is given intravenously to prevent kidney complications.
When ascites worsens during HCC treatment: New or worsening ascites can signal either disease progression (tumor involving more of the liver, blocking venous drainage) or drug-related liver toxicity. It should prompt reassessment — not simply an increase in diuretic dose.

Hepatic encephalopathy (HE) occurs when the liver cannot sufficiently process toxins (especially ammonia) that accumulate in the bloodstream and affect brain function. It can range from subtle cognitive changes (poor concentration, irritability, reversed sleep–wake cycle) to marked confusion, disorientation, and in severe cases, coma. HE is especially important to understand during HCC treatment because:

Systemic therapy can affect liver function and potentially precipitate or worsen HE
Dehydration from diarrhea (a common TKI side effect) can precipitate HE
Medications including sedatives and opioids are processed more slowly in a cirrhotic liver and can precipitate HE at lower doses than in non-cirrhotic patients

Management: Lactulose (a stool softener that reduces ammonia absorption from the gut) is the primary treatment for acute and chronic HE. Rifaximin (a non-absorbed antibiotic that alters gut flora) is added for patients with recurrent HE. Maintaining adequate nutrition is essential — restriction of protein was historically recommended but is now known to be harmful; adequate protein intake (1.2–1.5 g/kg/day) actually helps maintain muscle mass, which is an important ammonia buffer.

Portal Hypertension Questions to Ask Your Hepatologist

Do I have varices? When was my last endoscopy, and are they being monitored?
Am I on the right prophylactic medications (beta-blockers or band ligation) for my variceal risk?
Do I have ascites or is my diuretic regimen optimized?
Is my HCC treatment choice being influenced by my liver function and portal hypertension?

Managing Hepatitis B and C During HCC Treatment

The relationship between viral hepatitis and HCC treatment is critically important and sometimes misunderstood. Having a cured or controlled hepatitis infection does not mean the infection stops being relevant during cancer treatment.

Hepatitis B (HBV)

If you have chronic HBV (positive HBsAg or HBV DNA) or a past resolved HBV infection (positive anti-HBc with negative HBsAg), you are at risk of HBV reactivation during immunosuppressive or cytotoxic therapy. Reactivation can cause severe hepatitis, liver failure, and death — and it is almost entirely preventable.

Who needs prophylaxis: All HBV-positive patients on systemic HCC therapy should receive antiviral prophylaxis, typically entecavir or tenofovir alafenamide (TAF). This is started before or simultaneously with HCC therapy and continued for 6–12 months after stopping systemic treatment.
Checkpoint inhibitors and HBV: ICIs (atezolizumab, durvalumab, tremelimumab, pembrolizumab, nivolumab) carry particularly high reactivation risk. This includes patients who appear to be "immune" (anti-HBc positive, HBsAg negative) — reactivation in this group can happen unpredictably during ICI therapy. Discuss your antibody status with your team before starting ICI-based therapy.
HBV DNA monitoring: Even on prophylaxis, HBV DNA should be monitored every 3 months during therapy. A rising HBV DNA while on prophylaxis may indicate viral resistance and requires a change in antiviral agent.
Untreated active HBV and HCC: For patients newly diagnosed with HCC who are not yet on HBV treatment, starting antiviral therapy improves both liver function and HCC outcomes. Guidelines recommend starting antivirals even when HCC treatment is the immediate priority.

Hepatitis C (HCV)

Direct-acting antivirals (DAAs) cure HCV in more than 95% of people in 8–12 weeks. In the context of HCC, there are two important situations:

Newly diagnosed HCC with active HCV: Whether to treat HCV first or simultaneously with HCC treatment is a case-by-case decision. In patients with resectable or transplant-eligible HCC, HCV cure is strongly recommended before transplant and ideally before surgery. In patients with advanced HCC, treating HCV often improves liver function sufficiently to tolerate systemic therapy better, and does not significantly delay HCC treatment. Your liver tumor board should address this question.
Previously cured HCV: Sustained virologic response (SVR) after HCV treatment significantly reduces but does not eliminate HCC risk, especially in patients who had cirrhosis before cure. Continue surveillance indefinitely if you have cirrhosis. Some patients experience early HCC occurrence in the first 1–2 years after HCV cure; this does not mean the DAAs caused the cancer but rather that a pre-existing small tumor became clinically apparent after the liver inflammation from HCV resolved.

Hepatitis Management Questions

Is my HBV status fully evaluated, including surface antigen AND core antibody (anti-HBc)?
If I have past resolved HBV (anti-HBc positive), am I at reactivation risk during my HCC treatment, and do I need prophylaxis?
If I have active HCV, has the decision been made about when to treat it?
Who is managing my antiviral therapy — my hepatologist or oncologist?

Pregnancy, Fertility & Family Planning

Hepatocellular carcinoma is uncommon during the childbearing years (it usually develops later, on a background of long-standing liver disease), but it does occasionally occur in pregnancy, and fertility questions matter for younger patients. Care must be individualized with your oncology and hepatology team together with a maternal-fetal medicine (high-risk obstetrics) specialist.

HCC drugs and pregnancy. The targeted/oral drugs used for HCC — sorafenib, lenvatinib, regorafenib, and cabozantinib — are teratogenic/embryotoxic and are contraindicated in pregnancy. Bevacizumab (part of atezolizumab + bevacizumab) is also harmful to a pregnancy. Immune checkpoint inhibitors (atezolizumab, durvalumab/tremelimumab, nivolumab/ipilimumab) have limited pregnancy data and a theoretical risk of immune-mediated harm to the pregnancy, so they are generally avoided unless the benefit clearly outweighs the risk.
Underlying liver disease. Most HCC arises with cirrhosis and portal hypertension, which themselves raise pregnancy risk (variceal bleeding, decompensation). Pregnancy in this setting needs specialized hepatology and MFM co-management.
Locoregional and surgical options. Decisions about resection, ablation, or arterial therapies during pregnancy weigh fetal radiation/contrast exposure and timing — handled case by case at an experienced center.
Fertility & contraception. Discuss fertility preservation before starting systemic therapy when relevant. Effective contraception is advised during treatment (and for a period afterward) for both women and men, because these drugs can harm a pregnancy.

Questions to ask your doctor:

If I am or could become pregnant, which of my treatment options are safe, and who coordinates my care?
How does my liver disease (cirrhosis/varices) affect a possible pregnancy?
What fertility-preservation and contraception steps should I take before treatment?

Bone is one of the more common sites of HCC spread beyond the liver, occurring in approximately 5–10% of patients with advanced HCC. Bone metastases from HCC tend to be lytic (they dissolve bone structure) rather than blastic (bone-building), and they can cause significant pain and structural complications. The goals of bone metastasis management are pain control, fracture prevention, and maintaining your ability to move and function independently.

Types of bone complications:

Pain: Bone pain from HCC metastases is often described as a deep, aching, constant pain, sometimes worse at night or with weight-bearing. It may be the first symptom indicating bone involvement.
Pathologic fracture: When bone is weakened by tumor, it can break with minimal or no trauma. Weight-bearing bones (vertebrae, femur, hip) are particularly concerning. Report any sudden worsening of bone pain, especially with a specific event (even minor), immediately.
Spinal cord compression: If HCC involves vertebrae, it can compress the spinal cord — a neurological emergency. Symptoms: new weakness or numbness in arms or legs, difficulty walking, loss of bladder or bowel control. If you develop any of these, go to the emergency room immediately.

Management options:

Bone-protective therapy: Zoledronic acid (Zometa) IV every 4 weeks or denosumab (Xgeva) subcutaneous every 4 weeks reduce the risk of fracture and bone pain in patients with bone metastases. Ask your oncologist whether bone-protective therapy has been considered for your situation. Note: zoledronic acid requires good kidney function and is less commonly used in cirrhosis patients where kidney function may already be compromised; denosumab may be preferred in this setting.
Palliative radiation: External beam radiation therapy to a painful bone metastasis is highly effective, typically providing pain relief in 70–80% of patients. It is usually delivered in 5–10 sessions. Radiation oncology referral should be offered proactively for any painful bone site, not only when pain is uncontrollable.
Stereotactic body radiation (SBRT) for bone: A single high-dose session or very few sessions can provide durable local control for isolated bone metastases, including those in the spine, with minimal side effects. Ask your radiation oncologist if SBRT is an option for your bone metastasis.
Surgical stabilization: If a bone metastasis has fractured or is at high risk of fracture in a weight-bearing bone, orthopedic surgery can place rods or screws to stabilize the bone (prophylactic fixation). Your overall performance status and liver function determine surgical eligibility.

class="content-section" data-stage="advanced">

Clinical Trials — Finding and Enrolling

Clinical trials are particularly important in HCC because the field is evolving rapidly, with many promising combinations and new agents in development.

Trial	Agent(s)	Population	NCT Number
IMbrave150	Atezolizumab + bevacizumab	1L unresectable HCC	NCT03434379
HIMALAYA	Tremelimumab + durvalumab (STRIDE)	1L unresectable HCC	NCT03298451
IMbrave050	Atezolizumab + bevacizumab (adjuvant)	After curative resection/ablation	NCT04102098
EMERALD-1	TACE + durvalumab ± bevacizumab	Intermediate HCC (TACE-eligible)	NCT03778957
LEAP-012	TACE + lenvatinib + pembrolizumab	Intermediate HCC	NCT04246177
CheckMate 9DW	Nivolumab + ipilimumab	1L unresectable HCC	NCT04039607
KEYNOTE-937	Pembrolizumab (adjuvant)	After curative resection/ablation, CR	NCT03867084

ClinicalTrials.gov (clinicaltrials.gov): Search for “hepatocellular carcinoma” and filter by status (recruiting), location, and treatment type.
American Liver Foundation: liverfoundation.org — resources for liver cancer patients.
Blue Faery: The Adrienne Wilson Liver Cancer Association: bluefaery.org — a liver-cancer–specific patient organization with HCC education, support, and advocacy.
NORD (National Organization for Rare Disorders): rarediseases.org — patient assistance programs and rare-disease resources.
National Cancer Institute (NCI): 1-800-4-CANCER (1-800-422-6237) — free assistance finding clinical trials.
Your liver cancer center: Academic centers with dedicated liver tumor programs run trials not widely advertised. Ask your oncologist or hepatologist about available trials.

Clinical trial enrollment can feel overwhelming. Use this checklist of questions to evaluate whether a specific trial is right for your situation:

About the trial itself:

What is the experimental treatment? Is it a drug? An immunotherapy? A drug combination? A new delivery method (e.g., TACE with a novel agent)?
What phase is the trial (Phase 1 = safety, Phase 2 = early efficacy, Phase 3 = comparison to standard of care)?
What is the comparator arm? Is there a placebo arm, or is the comparison to current best therapy?
What is the primary endpoint: overall survival, progression-free survival, response rate? Overall survival trials are the gold standard for meaningful patient benefit.
Have interim results been published? What did the Phase 1 or Phase 2 data show?

About eligibility and logistics:

Does my liver function (Child-Pugh score) qualify me? Most trials require Child-Pugh A or B7 at minimum; some exclude any Child-Pugh B patients.
Do I need to discontinue my current treatment to enroll, and is that safe given my disease status?
How often do I need to come to the trial site? Can any visits be done locally?
What are the costs? Are research-related costs (study drug, study-required labs/scans) covered? What about travel?
Is there a caregiver requirement? Some trials require a caregiver to accompany patients for certain visits.

About risks and withdrawal:

What are the expected side effects, and how do they compare to current standard therapy?
Can I withdraw from the trial at any time and go back to standard treatment?
What happens to my care if the trial site closes or the study is terminated early?

The Barcelona Clinic Liver Cancer (BCLC) system is the internationally recommended staging system for HCC. It combines tumor characteristics, liver function (Child-Pugh score or ALBI grade), performance status, and cancer-related symptoms to assign a stage from 0 to D. Understanding where you fall in this system helps you understand why your team is recommending a specific treatment approach:

BCLC Stage 0 (Very early): Single tumor ≤2 cm, Child-Pugh A, PST 0. Treatment: Ablation (RFA/MWA) or resection. Cure rate: 70–80%. Transplant may be an option. Survival: >5 years expected.
BCLC Stage A (Early): Single tumor ≤5 cm or up to 3 tumors all ≤3 cm, Child-Pugh A–B, PST 0. Treatment: Resection, ablation, or liver transplant (if within Milan criteria). 5-year survival: 50–75%.
BCLC Stage B (Intermediate): Multinodular, no vascular invasion or extrahepatic spread, Child-Pugh A–B, PST 0. Treatment: TACE (transarterial chemoembolization). Median survival: 20–30 months. Some B stage patients can be downstaged by TACE and subsequently become transplant candidates.
BCLC Stage C (Advanced): Portal vein involvement, extrahepatic spread (lymph nodes, lung, bone, adrenal), PST 1–2. Treatment: Systemic therapy (atezolizumab+bevacizumab, lenvatinib, sorafenib, tremelimumab+durvalumab, or second-line options). Median survival: 13–19 months with current first-line immunotherapy combinations.
BCLC Stage D (End-stage): Child-Pugh C, PST 3–4. Best supportive care only; systemic therapy is generally too toxic in this setting. Prognosis: 3–4 months median. Palliative care and hospice discussion is appropriate.

BCLC staging is a guideline, not an absolute rule. Some patients are treated outside their technical BCLC stage when clinical judgment, multidisciplinary team input, or excellent liver reserve supports a more or less aggressive approach. The BCLC system has been updated in 2022 and is regularly revised as new evidence emerges; ask your team what BCLC stage they are assigning to your case and why they are recommending a specific treatment.

International Access & Regulatory Landscape

HCC epidemiology and treatment availability vary dramatically worldwide. Hepatitis B is the dominant cause in East Asia and Africa, while hepatitis C, alcohol, and NASH predominate in the West.

Drug / Approach	US FDA	EMA (Europe)	PMDA (Japan)	Notes
Atezolizumab + bevacizumab	2020	2020	2020	Global first-line standard
Tremelimumab + durvalumab	2022	2023	2023	Alternative first-line
Lenvatinib	2018	2018	2018	First-line for ICI-ineligible
Donafenib	N/A	N/A	N/A	China NMPA approved 2021; sorafenib derivative
Sintilimab + IBI305	N/A	N/A	N/A	China NMPA approved; PD-1 + bevacizumab biosimilar
HAIC (Hepatic arterial infusion chemo)	Not standard	Not standard	Standard option	Widely used in Japan and China; FOLFOX-HAIC studies

BCLC (Barcelona Clinic Liver Cancer): The most widely used staging and treatment algorithm in Western countries. Updated 2022.
AASLD (American Association for the Study of Liver Diseases): US guidelines for HCC management, updated 2023.
NCCN (US): Comprehensive treatment algorithms, updated quarterly.
EASL (European Association for the Study of the Liver): European clinical practice guidelines, updated 2024.
APASL (Asian Pacific Association for the Study of the Liver): Addresses HBV-dominant epidemiology in Asia.
JSH (Japan Society of Hepatology): Uses a different staging system (JSH staging) with more aggressive treatment for intermediate/advanced disease, including hepatic arterial infusion chemotherapy (HAIC).
Health Canada / CADTH: Canadian drug access pathway.
NICE (UK): Technology appraisals for NHS access.
PMDA (Japan): Sorafenib, lenvatinib, regorafenib, and cabozantinib are approved. Lenvatinib received particularly wide adoption in Japan. HAIC (hepatic arterial infusion chemotherapy with FOLFOX) is standard of care in Japan for intermediate/advanced HCC with portal vein involvement and is not approved for this indication in the US or EU. The JSH (Japan Society of Hepatology) guidelines incorporate HAIC as a standard treatment option that is simply not available in Western countries because the clinical trials that validated it were conducted primarily in Japan and China.
NMPA (China): In addition to Western-approved agents, China has approved several locally developed therapies. Donafenib (a deuterium-modified version of sorafenib) was approved in 2021 based on the ZGDH3 trial showing non-inferiority to sorafenib with a better side effect profile. Sintilimab (an anti-PD-1) + bevacizumab biosimilar received conditional approval. Camrelizumab + rivoceranib was approved by NMPA in 2023 based on the CARES-310 trial showing OS benefit over sorafenib; this combination has also received FDA approval consideration. These therapies are not yet available in the US or EU but represent the expanding global HCC treatment landscape.
Korea: KLCA-NCC (Korean Liver Cancer Association-National Cancer Center) guidelines are updated annually and include HAIC as an option for portal vein tumor thrombus, reflecting evidence primarily from Korean and Japanese trials.

Access for international patients: If you are considering traveling to another country for HCC therapy that is not available in your country — such as HAIC in a patient who has progressed on standard Western therapies — the major academic centers in Japan (National Cancer Center Japan, Osaka University Hospital), Korea (Seoul National University, Samsung Medical Center), and China (Zhongshan Hospital Fudan University) regularly evaluate international patients. The process involves sending records in advance for multidisciplinary review and requires a referral pathway; your hepatologist can facilitate.

Failed & De-Adopted Therapies

Knowing what has been tried and did not work is important. Understanding past failures helps you evaluate new options and avoid treatments that have already been studied and found ineffective.

FAILED The CheckMate 459 phase 3 trial (NCT02576509) compared nivolumab monotherapy to sorafenib as first-line treatment. Despite promising phase 1/2 data (CheckMate 040), the phase 3 trial did not meet its primary endpoint of overall survival improvement. Nivolumab monotherapy is no longer recommended as first-line treatment for HCC.

NUANCED Pembrolizumab is in fact an FDA-approved second-line option for HCC previously treated with sorafenib (accelerated approval in 2018, based on KEYNOTE-224). The global KEYNOTE-240 phase 3 trial narrowly missed its pre-specified statistical significance thresholds for OS and PFS, but a separate phase 3 trial, KEYNOTE-394, later confirmed significant improvements in overall survival, progression-free survival, and response — so the approval was maintained. It remains a valid second-line immunotherapy choice (see the Second-Line table above).

INSUFFICIENT Bevacizumab alone has modest activity in HCC but is not sufficiently effective as monotherapy. Its role is as a combination partner with atezolizumab, not as a standalone treatment.

FAILED Sunitinib was compared to sorafenib in a phase 3 trial but showed inferior overall survival with more toxicity. It has no role in HCC treatment.

FAILED Brivanib failed to demonstrate superiority over sorafenib as first-line (BRISK-FL) and failed to improve survival versus placebo as second-line (BRISK-PS). Development was discontinued.

FAILED Adding the EGFR inhibitor erlotinib to sorafenib did not improve outcomes over sorafenib alone. EGFR targeting has not proven effective in HCC.

Why this matters: If someone suggests one of these therapies, you now know its history. Always ask your oncologist: “Has this been tested in a phase 3 trial for HCC, and what were the results?”

Am I eligible for liver transplant? Should I be evaluated now?
If I exceed Milan criteria, can locoregional therapy downstage me into eligibility?
Is living donor liver transplant an option for me?
What is the sequence of treatments if my first-line therapy stops working?
Are there clinical trials open for my situation?
What is the status of my hepatitis B/C treatment during cancer therapy?
If I have had a transplant, what treatments are safe for me if HCC recurs?
Should I be considered for TACE + immunotherapy combination?

Managing Side Effects of HCC Systemic Therapy

Each class of HCC systemic therapy has a characteristic side-effect profile. Understanding what to expect — and which symptoms require immediate reporting versus which can be managed at home — is essential for safe treatment. In HCC, side effect management is complicated by the fact that you have both cancer AND liver disease, meaning some side effects that would be minor in a healthy liver can be more serious in your situation.

TKIs are oral daily pills. Their side effects are class effects to varying degrees, with individual differences between agents:

Hand-foot skin reaction (HFSR / palmar-plantar erythrodysesthesia):

Most common with sorafenib and regorafenib. Redness, tenderness, thickening of skin on palms and soles, with hyperkeratotic plaques in areas of pressure. Can progress to blisters and open sores that make walking or using hands painful.
Prevention: Start a urea-based moisturizing cream (e.g., AmLactin 12%, Eucerin) on palms and soles 1–2 weeks before starting therapy. Avoid activities that cause friction or pressure (tight shoes, heavy manual work). Wear padded socks and comfortable footwear.
Management: Grade 1 (redness, no pain) — continue drug, optimize moisturizing. Grade 2 (pain limiting daily activities) — dose reduction per protocol, wound care. Grade 3 (ulceration, extreme pain) — hold drug, dermatology referral. Report to your team immediately if blisters or open sores develop.

Hypertension (all TKIs, especially sorafenib and lenvatinib):

Blood pressure rises within the first weeks of therapy and is an on-target effect (VEGF inhibition). Monitor blood pressure at home with a cuff at least twice weekly during the first month.
Report a single reading above 160/100 mmHg or any readings above 150/95 on two consecutive days. Antihypertensive therapy (amlodipine is commonly used) is added or escalated promptly — uncontrolled hypertension requires dose reduction or hold.
Severe hypertension (>180/110) or hypertensive crisis (headache, visual changes, confusion) requires emergency evaluation.

Diarrhea:

Very common with all TKIs. For mild diarrhea (1–3 loose stools per day above baseline): use loperamide (Imodium) promptly, increase fluid intake, avoid high-fiber foods and dairy until stools normalize.
Report diarrhea that is persistent (>24 hours) despite loperamide, associated with blood or mucus, accompanied by severe cramping or fever, or resulting in weakness or dizziness (dehydration). In cirrhosis patients, severe diarrhea can trigger hepatic encephalopathy by disrupting ammonia balance.

Fatigue and appetite loss:

Very common. Energy conservation strategies: prioritize activities, rest before exertion, optimize sleep hygiene. Nutritional support (high-calorie, high-protein supplements) should be started proactively if intake is declining — do not wait until significant weight loss occurs.
Report fatigue that is sudden or markedly worse than your baseline in a short period, as this can signal hepatic decompensation or new-onset anemia.

Thyroid dysfunction (especially lenvatinib):

Hypothyroidism occurs in up to 60% of patients on lenvatinib. Symptoms: fatigue, cold intolerance, constipation, weight gain, depression. Your team should check thyroid function tests (TSH/free T4) at baseline and every 4–8 weeks.
Hypothyroidism from lenvatinib responds well to levothyroxine replacement and does not require stopping the cancer drug.

Checkpoint inhibitors (atezolizumab, durvalumab, tremelimumab, pembrolizumab, nivolumab) work by releasing the immune system’s brakes. This can cause the immune system to attack normal tissues — a pattern called immune-related adverse events (irAEs). IrAEs can affect virtually any organ. The key principle: new or changing symptoms during ICI therapy should be evaluated for irAE until proven otherwise, because many irAEs are treatable and reversible if caught early, but can be severe or fatal if ignored.

Immune-related hepatitis (immune-mediated liver inflammation):

Particularly relevant in HCC because you already have liver disease. Occurs in approximately 5–10% of patients on dual ICI (tremelimumab + durvalumab) and less with single agents.
Symptoms: yellowing of skin or eyes (jaundice), dark urine, abdominal pain, nausea, or simply new fatigue with lab abnormalities found on routine monitoring.
Action: Your team monitors liver enzymes (AST/ALT) every 2–4 weeks. If labs show significant rise, the ICI is held and steroids are given. This is not a reason to panic — it is a manageable side effect when caught at standard monitoring visits. The challenge in HCC is distinguishing immune hepatitis from disease progression; imaging and sometimes biopsy are used to differentiate.

Pneumonitis (lung inflammation):

New cough, shortness of breath, or decreased exercise tolerance during ICI therapy should prompt immediate contact with your oncology team. Pneumonitis can progress rapidly.
Do not assume respiratory symptoms are COVID-19 or a common cold without contacting your team first.

Endocrine irAEs:

Hypothyroidism: very common (20–30% of patients). Treated with levothyroxine; does not require stopping ICI.
Adrenal insufficiency: rare but serious. Symptoms: fatigue, weakness, low blood pressure, dizziness, nausea, dark skin. Can be life-threatening if not treated. Requires cortisol replacement and usually means stopping ICI.
Diabetes (ICI-induced type 1 diabetes): rare but sudden-onset. Symptoms: extreme thirst, frequent urination, weight loss. Can present as diabetic ketoacidosis (DKA), a medical emergency. Report any of these symptoms immediately.

Bevacizumab-specific risks (in the atezolizumab + bevacizumab regimen):

Variceal bleeding: Bevacizumab inhibits the growth of new blood vessels, including the collateral veins that form in portal hypertension. This can increase variceal bleeding risk. This is why endoscopic screening and treatment of high-risk varices is mandatory before starting this regimen (see the portal hypertension section above).
Hypertension and proteinuria: Blood pressure monitoring and urine protein checks are required. Significant proteinuria (>3.5 g/24h) requires bevacizumab hold or discontinuation.
Wound healing and surgical procedures: Bevacizumab must be held for 4–6 weeks before any elective surgery and for at least 4 weeks after surgery, because it impairs wound healing. Discuss with your oncologist before any planned procedure.

Immunotherapy Red Flag Symptoms — Contact Your Team Same Day

Jaundice, dark urine, or significant fatigue with any yellowing
New shortness of breath, cough, or chest pain
Extreme thirst, frequent urination, or unexpected weight loss
New rash covering >30% of body or any blistering rash
Severe diarrhea (>6 stools/day) or blood in stool
Severe headache, vision changes, muscle weakness
Fever above 38.5°C (101.3°F) at any time during ICI therapy

When in doubt, call your oncology triage line. IrAEs are manageable when caught early.

class="content-section" data-stage="resources">

Specialty Centers

HCC outcomes are significantly better at centers with multidisciplinary liver tumor boards, experienced hepatobiliary surgeons, transplant programs, interventional radiology, and access to clinical trials. A second opinion from an academic liver cancer center is strongly recommended.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

Huntsman Cancer Institute (HCI) — University of Utah

NCI-designated Comprehensive Cancer Center with multidisciplinary liver tumor program

Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112
Phone: 801-585-0303
Programs: Multidisciplinary Liver Tumor Board, Hepatobiliary Surgery, Interventional Radiology (TACE, Y-90, ablation), Medical Oncology, Hepatology, Liver Transplant Program (through University of Utah Health). Active HCC clinical trial portfolio including immunotherapy combinations and novel agents.

Why it matters. HCI is the only NCI-designated Comprehensive Cancer Center in the Mountain West region. Its multidisciplinary liver tumor board brings together hepatobiliary surgeons, transplant surgeons, medical oncologists, hepatologists, interventional radiologists, and radiation oncologists to review every case.

University of Utah Transplant Program

Academic liver transplant center

Location: Salt Lake City, UT
Phone: 801-581-2121
Services: Liver transplant evaluation for HCC, living donor liver transplant program, pre-transplant locoregional therapy coordination, post-transplant surveillance.

Intermountain Health Liver Program

Location: Salt Lake City, UT
Phone: 801-442-2000
Programs: Hepatology, liver disease management, hepatobiliary surgery, interventional radiology. Integrated network across Utah and the Intermountain West.

Mayo Clinic Arizona

Location: 5777 E Mayo Blvd, Phoenix, AZ 85054
Phone: 480-301-8000
Programs: Liver transplant center, hepatobiliary surgery, interventional radiology, active HCC clinical trials.

University of Colorado Anschutz Medical Campus

Location: 1665 Aurora Ct, Aurora, CO 80045
Phone: 720-848-0000
Programs: NCI-designated Comprehensive Cancer Center. Liver transplant program, multidisciplinary liver tumor board.

How to choose. Huntsman Cancer Institute / U of U = NCI Comprehensive Cancer Center with integrated liver tumor board AND transplant program. Intermountain Health = community health system with hepatology and interventional radiology, broad geographic coverage. Mayo Clinic Arizona = high-volume transplant center accessible from the Mountain West.

Information verified May 2026. Availability changes — confirm with each institution directly.

MD Anderson Cancer Center

Location: Houston, TX · Phone: 877-632-6789
One of the world’s largest liver cancer programs. Extensive HCC clinical trial portfolio including immunotherapy combinations, TACE+ICI, and novel agents. Hepatobiliary surgery and liver transplant.

Memorial Sloan Kettering Cancer Center

Location: New York, NY · Phone: 212-639-2000
Major hepatobiliary surgery and liver transplant program. Leading HCC clinical trials. Interventional oncology with TACE and Y-90.

UCSF Helen Diller Comprehensive Cancer Center

Location: San Francisco, CA · Phone: 415-353-9888
Pioneered the UCSF criteria for expanded transplant eligibility. High-volume liver transplant center. Active HCC research program.

Mayo Clinic Rochester

Location: Rochester, MN · Phone: 507-538-3270
Comprehensive liver cancer program with transplant, surgery, interventional radiology, and clinical trials. National reach.

Cleveland Clinic

Location: Cleveland, OH · Phone: 866-588-2264
Liver transplant center, hepatobiliary surgery, interventional radiology. Active liver cancer clinical trials.

Mount Sinai Liver Cancer Program

Location: New York, NY · Phone: 212-241-6500
Recanati/Miller Transplantation Institute. Multidisciplinary liver tumor board. Extensive hepatology and liver cancer expertise.

Johns Hopkins Sidney Kimmel Cancer Center

Location: Baltimore, MD · Phone: 410-955-5000
Liver transplant center, hepatobiliary surgery, clinical trials including immunotherapy combinations for HCC.

VA Hepatocellular Carcinoma Care

HCC is a recognized condition among Veterans, particularly those with hepatitis C (treated or cured) and alcohol-related liver disease. The VA system manages HCC through its hepatology and oncology programs, with transplant referrals to VA-affiliated academic centers.

VA Salt Lake City Health Care System: 801-582-1565
Referral to HCI or U of U Transplant for transplant evaluation through VA community care
VA Hepatitis C screening and treatment programs reduce but do not eliminate HCC risk

VA Cancer Care: cancer.va.gov
VA Community Care: 1-877-881-7618

Princess Margaret Cancer Centre (UHN), Toronto

Location: 610 University Avenue, Toronto, ON M5G 2M9
Phone: 416-946-4501
Programs: Multi-Organ Transplant Program, hepatobiliary surgery, interventional radiology, active HCC clinical trials.

BC Cancer — Vancouver Centre

Location: Vancouver, BC
Phone: 604-877-6000
Programs: Hepatobiliary cancer program. Liver transplant through Vancouver General Hospital.

McGill University Health Centre, Montreal

Location: Montréal, QC
Phone: 514-934-1934
Programs: Liver transplant program, hepatobiliary surgery, HCC clinical trials.

Canadian Cancer Society helpline: 1-888-939-3333
Canadian Liver Foundation: liver.ca

International Centers of Excellence for HCC

Hospital Clínic Barcelona, Spain: Home of the BCLC staging system. One of the world’s leading liver cancer research and treatment centers.
National Cancer Center, Tokyo, Japan: JSH guidelines center. Pioneered HAIC and hepatic arterial approaches.
Queen Mary Hospital / University of Hong Kong: Leading center for HBV-related HCC and living donor liver transplant research.
Asan Medical Center, Seoul, South Korea: One of the world’s highest-volume liver transplant and hepatobiliary surgery centers.
King’s College Hospital, London, UK: Major liver transplant and hepatology center. NICE-guided HCC management.
Sun Yat-sen University Cancer Center, Guangzhou, China: Leading center for HBV-related HCC, FOLFOX-HAIC, and TACE-ICI combination research.

Caregiver Guidance

Caring for someone with HCC involves managing both a cancer and a chronic liver condition. This dual challenge creates unique demands on caregivers.

Medication management: Many common medications (including over-the-counter pain relievers like acetaminophen and NSAIDs) must be used with extreme caution or avoided in patients with liver disease. Always check with the hepatologist before giving any new medication.
Nutrition: Patients with cirrhosis often need a high-protein, low-sodium diet. Malnutrition is common and worsens outcomes. A registered dietitian with liver disease experience is invaluable.
Fluid management: Ascites (fluid accumulation in the abdomen) is common in advanced cirrhosis. Track daily weight and abdominal girth. Report rapid weight gain (>2 pounds per day) to the medical team.
Encephalopathy: Hepatic encephalopathy (confusion caused by the liver’s inability to clear toxins) can come on suddenly. It is treated with lactulose and rifaximin. Know the early signs: personality changes, sleep disturbance, confusion.

The transplant waiting period is psychologically difficult. Hope and anxiety coexist. Regular communication with the transplant coordinator is essential.
Advance directives should be discussed early, when the patient is well enough to participate.
Caregiver burnout is real. Reach out to the American Liver Foundation (liverfoundation.org) for support groups and resources.
Financial assistance: Liver cancer treatment and transplant evaluation are expensive. Social workers at cancer centers can help navigate insurance, disability, and financial assistance programs.

Referral Routing Guidance
Suspected HCC (any liver mass in a patient with cirrhosis or risk factors): Refer to hepatologist AND liver tumor board. Order multiphasic CT or MRI with LI-RADS reporting. Do not delay for AFP results.
Confirmed early-stage HCC: Refer to hepatobiliary surgery AND transplant evaluation simultaneously. Time matters — transplant evaluation takes weeks.
Intermediate/advanced HCC: Multidisciplinary tumor board review required before treatment. Medical oncology, interventional radiology, hepatology, and transplant surgery input.
Decompensated liver disease (Child-Pugh C) with HCC: Transplant evaluation is the priority. Most systemic and locoregional therapies are not safe. Palliative care consultation.
Post-transplant recurrence: Medical oncology (TKIs only — no checkpoint inhibitors). Consider interventional radiology if amenable.

Caring for someone with HCC is one of the most demanding caregiving roles because you are managing two serious conditions simultaneously — cancer and liver disease — each with its own monitoring requirements, medication complexity, and potential for rapid change. Caregiver burnout is not a sign of weakness or insufficient love; it is a predictable physiological and psychological response to sustained high demands without recovery time.

Signs of caregiver burnout to watch for in yourself:

Persistent fatigue that sleep does not resolve
Increasing withdrawal from social contacts and activities you previously enjoyed
Feeling resentful toward the person you are caring for, then feeling guilty about the resentment
Declining attention to your own health (skipping your own medical appointments, not eating well, not exercising)
Increased use of alcohol or medications to cope
Feeling helpless, hopeless, or that nothing you do matters

Practical strategies:

Build a care team, not a care solo: Identify two or three people (family, friends, community members) who can be called upon for specific tasks — driving to appointments, sitting with your loved one for a few hours, handling grocery runs. Give them specific, assignable tasks rather than open-ended "let me know if you need anything."
Respite care: Short-term placement in a skilled nursing facility, adult day programs, or in-home respite services allows caregivers regular breaks. Hospice programs in particular are required to offer respite care as part of the Medicare hospice benefit.
Caregiver support groups: The CJD Foundation, the American Liver Foundation, and the Liver Cancer Connect organization all offer caregiver-specific support programs and forums. Speaking with others who are managing the same dual complexity (cancer + liver disease) provides both practical knowledge and emotional validation unavailable elsewhere.
Mental health support for caregivers: Individual therapy (in person or via telehealth) is specifically beneficial for caregivers facing anticipatory grief and complicated emotions. Ask your loved one’s palliative care team or social worker to also support you, not just the patient. This is an appropriate request and one the palliative care team expects.

Caregivers often observe changes in the patient that the patient cannot accurately report themselves — confusion, personality change, physical decline, medication non-adherence, and changes in function. Your observations are clinically important, and communicating them effectively makes a real difference in care quality.

Before each appointment:

Write down specific observations from the past interval, with dates and details: "He/she became confused for about 4 hours on Tuesday evening and returned to normal overnight" is much more useful than "He/she seems more confused."
Note any medication missed, doses changed, or new symptoms since the last visit
Prepare your 2–3 priority questions; the appointment may run short, so prioritize

During the appointment:

Ask if you can have a few minutes to speak with the team privately, or if the team can speak with you alone briefly after the visit, to report observations the patient may not share or may not accurately recall. This is a reasonable and respected request in oncology and hepatology care.
Ask for explanations of lab results in terms you can monitor at home: "What should his/her bilirubin be by the next visit? When should I call?"
Confirm who to call after hours and on weekends, and what specific symptoms warrant calling vs. going to the emergency room

Nutrition, Muscle Preservation, and Quality of Life

Malnutrition and loss of muscle mass (sarcopenia) affect more than 50% of people with cirrhosis and HCC. Sarcopenia is a powerful independent predictor of worse HCC outcomes — not because it reflects disease severity directly, but because muscle mass is a reservoir for amino acid metabolism, an ammonia buffer, and a determinant of how well you tolerate treatment. Maintaining or improving nutritional status is not optional; it is part of your cancer treatment.

Protein intake — the critical point

For decades, patients with liver disease were told to restrict protein to prevent hepatic encephalopathy. We now know this was wrong. Protein restriction worsens sarcopenia, accelerates muscle loss, and paradoxically worsens encephalopathy by eliminating the ammonia-buffering capacity of muscle. Current guidelines recommend:

1.2–1.5 grams of protein per kilogram of body weight per day for people with cirrhosis (higher than the general population recommendation of 0.8 g/kg)
Plant-based and dairy protein sources may be better tolerated than red meat protein in those prone to encephalopathy, because they produce less ammonia during digestion
Branched-chain amino acids (BCAAs) — leucine, isoleucine, and valine — are a form of protein supplement with specific evidence in cirrhosis; EASL guidelines support their use. BCAAs may help preserve muscle mass and improve quality of life during HCC treatment.

Caloric intake and meal timing

Target 30–35 kcal/kg/day, distributed across 4–6 small meals rather than 2–3 large ones, because a cirrhotic liver has limited glycogen storage capacity and cannot sustain adequate glucose levels through prolonged overnight fasting
A late-evening snack (LES) — typically a protein-rich snack within 2 hours of bedtime — is specifically recommended in EASL guidelines for cirrhosis to prevent overnight fasting-induced catabolism
If nausea or anorexia is limiting your intake (often due to TKI side effects), proactive antiemetics, appetite stimulants, or supplemental nutrition via oral protein supplements may be recommended by your dietitian

Sodium and fluid management with ascites

2,000 mg sodium/day is the recommended limit for patients with ascites — equivalent to approximately one teaspoon of table salt. This includes all salt added in cooking and hidden sodium in processed foods, canned soups, deli meats, condiments, and restaurant meals
Fluid restriction is generally not recommended unless sodium levels fall below 125 mEq/L
Work with a liver-disease registered dietitian rather than a general oncology dietitian if possible; managing simultaneously low sodium, high protein, adequate calories, and often a specific pattern to avoid encephalopathy requires expertise in cirrhosis nutrition

Physical activity

Physical inactivity accelerates sarcopenia. Even in the setting of advanced cirrhosis and HCC, supervised physical activity is safe and beneficial:

Moderate aerobic exercise (walking, cycling) for 30 minutes on most days of the week improves muscle mass, functional capacity, and quality of life
Resistance training (light weights, resistance bands) specifically targets sarcopenia and is increasingly recommended as part of HCC rehabilitation
Physical therapy or a physical medicine and rehabilitation consultation is appropriate for patients with significant deconditioning

Nutrition Questions to Ask Your Team

Do I have malnutrition or sarcopenia? Has this been assessed (grip strength, CT-based muscle assessment)?
Can you refer me to a registered dietitian with liver disease expertise?
Am I consuming enough protein, and do I have a late-evening snack?
Are my treatment side effects (nausea, diarrhea, appetite loss) being treated aggressively enough to protect my nutritional status?

Palliative Care and Goals of Care

Palliative care is specialized medical care focused on providing relief from symptoms, pain, and stress of a serious illness — regardless of prognosis or whether you are pursuing curative or life-prolonging treatment. It is not the same as hospice care, and it is not about giving up. For HCC, early integration of palliative care alongside cancer-directed treatment consistently improves quality of life, reduces unnecessary hospitalizations, and in some studies has been associated with longer survival — because better symptom control means better treatment tolerance.

Symptoms that palliative care commonly addresses in HCC

Pain: Hepatic pain from tumor capsule stretch or infarction is common and underreported. A palliative care specialist can optimize pain management including the challenging situation of using opioids in patients with impaired hepatic metabolism — where standard dosing guidelines do not apply.
Fatigue: The most common symptom in HCC. Often multifactorial (anemia, portal hypertension, medication side effects, muscle loss, depression). Palliative care teams identify treatable contributors and help with energy conservation strategies and realistic activity planning.
Pruritus (itching): Cholestatic itch from bile duct obstruction or impaired bile excretion can be debilitating. Cholestyramine, rifampicin, and naltrexone are options; a palliative care or hepatology consultation can find the most effective approach for your specific situation.
Nausea and appetite loss: Particularly from TKIs and locoregional treatments. Proactive antiemetic regimens and appetite stimulants improve nutritional intake and quality of life.
Anxiety and depression: Common and undertreated in HCC. Palliative care teams include social workers and may initiate referrals to psychology or psychiatry, and can manage medications adjusted for liver function.

Advance care planning

Advance care planning (ACP) is the process of thinking through and documenting your wishes for medical care in the future, particularly if you become unable to speak for yourself. In HCC, where the disease course can change rapidly, this conversation is important to have early:

Identify a healthcare proxy/power of attorney — someone who understands your values and can make decisions aligned with your wishes if you cannot
Advance directive or living will — documents that record your preferences about specific interventions (CPR, mechanical ventilation, tube feeding, ICU admission) under defined circumstances. These are legally recognized in all US states, though the specific forms vary by state.
POLST (Physician Orders for Life-Sustaining Treatment) — a portable medical order, signed by a physician, that travels with you to hospitals, emergency rooms, and care facilities. Appropriate for patients with serious illness who have a clear picture of their goals. A POLST is not a substitution for conversation with your team — it is the documented outcome of that conversation.

When to consider hospice

Hospice care in the US is available when a physician certifies that if the illness follows its expected course, the prognosis is 6 months or fewer. For HCC patients with Child-Pugh class C liver function or with disease that has progressed through all available systemic therapies, an honest discussion about hospice eligibility and benefit is appropriate and humane. Hospice provides:

Skilled nursing visits to the home, several times per week
Medications for pain, anxiety, nausea, and dyspnea at no cost to Medicare beneficiaries
Medical equipment (hospital bed, wheelchair, oxygen)
Social work, chaplaincy, and bereavement support for the family

Studies consistently show that patients in hospice live at least as long as similar patients pursuing aggressive treatment near the end of life — and report better quality of life. The decision is reversible: a patient can leave hospice to pursue further treatment and re-enroll later.

Goals-of-Care Questions to Ask Your Team

What are we hoping to achieve with this treatment — cure, life prolongation, or symptom control?
If this treatment stops working, what are the next options, and what happens if there are no more treatment options?
Can you refer me to palliative care? I understand palliative care is not the same as giving up.
Who should I speak to about advance directives?

Financial Toxicity — The Cost of HCC Treatment

HCC therapies carry some of the highest per-month drug costs of any cancer treatment. Understanding the financial landscape and the assistance resources available is essential planning, not an admission that cost will override care decisions.

Estimated monthly drug costs (without insurance, 2024 US list prices)

Atezolizumab + bevacizumab (Tecentriq + Avastin): ~$25,000–$30,000/month combined. Genentech/Roche offers the Genentech Access Solutions program for uninsured and underinsured patients.
Tremelimumab + durvalumab (Imfinzi + STRIDE regimen): ~$20,000+/month. AstraZeneca offers AZ&Me Prescription Savings Program.
Lenvatinib (Lenvima): ~$18,000–$22,000/month. Eisai Oncology patient assistance through Harbor of Hope.
Sorafenib (Nexavar): ~$12,000–$15,000/month. Bayer REACH patient assistance program.
Regorafenib (Stivarga): ~$15,000–$18,000/month. Bayer REACH patient assistance program.
Cabozantinib (Cabometyx): ~$18,000–$22,000/month. Exelixis patient assistance programs.
Ramucirumab (Cyramza): IV infusion; pricing varies by facility and dose.

Ways to reduce out-of-pocket costs

Manufacturer patient assistance programs (PAPs): Most major HCC drugs have PAPs for patients who meet income and insurance criteria. Your oncology social worker or practice administrator is your best advocate for navigating these programs — ask specifically at your first visit.
Co-pay assistance cards: Available from most manufacturers for commercially insured patients (note: co-pay cards cannot be used with Medicare/Medicaid). They can reduce your co-pay to $0 for the duration of your treatment.
Medicare patients: The Medicare Part D Extra Help (Low Income Subsidy) program provides significant cost-sharing reduction for qualifying patients. Your oncology social worker can help you apply. Medicare Part B covers some infused regimens (bevacizumab, ramucirumab) under the outpatient benefit rather than Part D, which may reduce cost.
Cancer-specific financial assistance organizations: The Patient Advocate Foundation, CancerCare, the HealthWell Foundation, and the Liver Cancer Connect organization all provide financial assistance or referrals specifically for HCC patients.
Clinical trials: If you are enrolled in a clinical trial, the investigational drug is typically provided at no cost. Standard-of-care costs during trial participation are usually covered by insurance per normal terms.

Financial Navigation Questions

Can I speak with your oncology social worker or financial counselor?
Is there a manufacturer patient assistance program for my specific drug?
Does this center have a financial navigator specifically for oncology patients?
What is my estimated total out-of-pocket cost per month, including drug, infusions, labs, and visits?

Glossary

Ablation: Destruction of a tumor using heat (radiofrequency or microwave) or cold (cryoablation), without surgical removal.
AFP (Alpha-fetoprotein): A blood protein produced by the liver. Elevated AFP levels can indicate HCC, though not all HCC tumors produce AFP.
ALBI grade: Albumin-bilirubin grade. A simple score of liver function using only two blood tests. Subdivides Child-Pugh A patients for better prognostication.
Ascites: Accumulation of fluid in the abdominal cavity. A sign of decompensated cirrhosis.
BCLC: Barcelona Clinic Liver Cancer staging system. The most widely used HCC staging and treatment allocation system in Western countries.
Bevacizumab: An antibody that blocks VEGF (vascular endothelial growth factor), cutting off a tumor’s blood supply. Used with atezolizumab for HCC.
Bridging therapy: Treatment given to prevent tumor progression while a patient waits for liver transplant.
Child-Pugh score: A scoring system (A, B, or C) that rates how well the liver is functioning. Determines which HCC treatments are safe.
Cirrhosis: Severe scarring of the liver from chronic damage. The main risk factor for HCC.
Downstaging: Using locoregional therapy to shrink tumors to within transplant eligibility criteria (typically Milan criteria).
Encephalopathy: Confusion and cognitive changes caused by the liver’s inability to clear toxins from the blood.
HCC: Hepatocellular carcinoma. The most common type of primary liver cancer.
Immunotherapy: Treatment that helps the immune system recognize and attack cancer cells. Checkpoint inhibitors like atezolizumab and durvalumab are used in HCC.
LI-RADS: Liver Imaging Reporting and Data System. A standardized way to classify liver observations on CT or MRI.
Locoregional therapy: Treatments that target tumors locally, including TACE, Y-90 radioembolization, and ablation.
Milan criteria: The standard criteria for liver transplant eligibility in HCC: single tumor ≤5 cm or up to 3 tumors ≤3 cm each, no vascular invasion.
NASH/MASLD: Non-alcoholic steatohepatitis / metabolic dysfunction-associated steatotic liver disease. A growing cause of cirrhosis and HCC.
Portal vein thrombosis: Blood clot or tumor invasion in the main blood vessel entering the liver. A sign of advanced HCC that limits treatment options.
TACE: Transarterial chemoembolization. A procedure that delivers chemotherapy directly into the tumor’s blood supply and blocks that artery.
TKI: Tyrosine kinase inhibitor. Oral drugs (sorafenib, lenvatinib, cabozantinib, regorafenib) that block tumor growth signals.
Varices: Enlarged veins in the esophagus or stomach caused by portal hypertension. Can bleed dangerously, especially with bevacizumab.
Y-90 (TARE): Transarterial radioembolization. Delivery of radioactive yttrium-90 beads into the tumor’s blood supply.
Ablation: Image-guided destruction of a tumor without surgery. Radiofrequency ablation (RFA) uses electrical current to heat and destroy tumor cells; microwave ablation (MWA) uses microwave energy. Both are delivered through a needle through the skin and are most effective for tumors under 3 cm. Ablation is the standard curative approach for BCLC-0 and small BCLC-A tumors.
ALBI Grade: Albumin-Bilirubin grade — a scoring system for liver function using only serum albumin and bilirubin. Grades 1, 2, and 3 correspond to good, moderate, and poor liver function. ALBI is increasingly used alongside Child-Pugh because it is fully objective and better stratifies outcomes within Child-Pugh A.
Portal Hypertension: Elevated pressure in the portal venous system, most commonly from cirrhosis. Leads to varices (enlarged veins in the esophagus or stomach that can bleed dangerously), ascites, and splenomegaly. Severity directly influences which HCC treatments are safe to use.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians treating HCC across multiple countries. Key sources are listed below.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
NCCN Guidelines for Clinicians — Hepatocellular Carcinoma (nccn.org) — Treatment algorithms followed by oncologists
American Liver Foundation (liverfoundation.org) — Patient education and support for liver diseases
National Cancer Institute (NCI) (cancer.gov) — Comprehensive liver cancer information

Key Guideline and Trial References

IMbrave150: Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. (NCT03434379)
HIMALAYA: Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8). (NCT03298451)
IMbrave050: Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050). Lancet. 2023;402(10415):1835–1847. (NCT04102098)
REFLECT: Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. Lancet. 2018;391(10126):1163–1173.
CELESTIAL: Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. (NCT01908426)
REACH-2: Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased AFP (REACH-2). Lancet Oncol. 2019;20(2):282–296. (NCT02435433)
RESORCE: Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE). Lancet. 2017;389(10064):56–66. (NCT01774344)
AASLD 2023: Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965.
BCLC 2022 Update: Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693.
EASL 2024: European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2024.

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot diagnose, stage, or treat anyone. It does not know your tumor burden, liver function, viral status, comorbidities, or personal preferences. Only your medical team can build an actual plan.
HCC treatment is changing rapidly. New trial results, TACE+ICI combinations, and guideline updates occur frequently. Every time-sensitive fact should be re-verified with your team, on FDA.gov, and on ClinicalTrials.gov.
Drug approvals and availability vary by country. This guide focuses primarily on FDA-approved therapies. Access differs significantly in Asia, Europe, and other regions, where different drugs and approaches may be standard.
Individual outcomes cannot be predicted. Staging systems describe populations, not individuals. Two patients with the same BCLC stage can have very different courses.
Transplant availability varies enormously. Organ availability, wait times, and eligibility criteria differ by region, transplant center, and insurance coverage.

A final word. An HCC diagnosis is frightening, especially when it comes on top of existing liver disease. But the treatment landscape has genuinely transformed since 2020. Immunotherapy combinations have changed the outlook for advanced disease. Locoregional therapies continue to improve. Transplant eligibility has expanded. Get to a multidisciplinary liver tumor board. Understand your staging and liver function. Ask about transplant eligibility. Ask about clinical trials. Bring this guide to your appointments. Help is real.

Appendix

Testing Treatments on a Copy of Your Own Tumor

Hepatocellular carcinoma (HCC) is a cancer where the same drug can produce very different results from one person to the next. Two patients with similar-stage tumors and the same BCLC classification can respond completely differently to sorafenib or atezolizumab. Part of the reason is biology: HCC arises from many different causes — hepatitis B, hepatitis C, alcohol-related liver disease, fatty liver disease — and each underlying cause leaves a distinct molecular fingerprint on the tumor. Add to that the variation in immune activity within each person's liver, and it becomes clear why "standard first-line therapy" is a starting point, not a guarantee. Functional tumor testing — growing a small copy of your tumor in a laboratory and testing drugs directly on it — is an emerging approach that aims to give your oncology team more information before committing to a particular treatment. For liver cancer specifically, this approach carries both real promise and real practical challenges that are worth understanding.

The most important thing to know: Functional tumor testing for HCC is investigational. It is not yet a standard part of liver cancer care, and no major guideline currently recommends it as a required step before choosing a treatment. If you pursue it, it works alongside — not instead of — your oncologist's clinical judgment, your imaging findings, your liver function tests, and your genomic profile. Think of it as an extra layer of information, not a replacement for any of the decisions your team already makes.

The basic idea

Every HCC tumor is shaped by two things: the cancer cells themselves, and the environment those cells grew up in. The liver is a complex organ with its own immune cells (Kupffer cells), structural support cells (stellate cells), and blood supply. A tumor growing inside a cirrhotic liver is under very different pressures than a tumor in a healthy liver, and those pressures affect how it responds to drugs. Standard genomic testing can identify some of the mutations driving a tumor, but it cannot always predict whether a specific drug will actually kill the tumor cells in a specific patient's body. That gap is what functional testing tries to fill.

The core idea is straightforward: take a small piece of your tumor, grow it in a controlled laboratory environment that mimics your liver's biology as closely as possible, and expose it to the drugs being considered for your treatment. If the tumor tissue dies when exposed to lenvatinib but survives sorafenib, that pattern may help guide which drug your oncologist reaches for first. For HCC in particular, researchers have also begun growing organoids alongside immune cells in co-culture systems, which gives an early-stage window into how a tumor might respond to immunotherapy combinations like atezolizumab plus bevacizumab. This work is still research-stage, but it represents one of the more promising directions in liver cancer functional testing.

The main approaches, from fastest to slowest

Tumor organoids

Turnaround: approximately 4–8 weeks | Most data available for HCC

Organoids are three-dimensional mini-tumors grown from your actual cancer cells. For liver cancer, this approach has a meaningful head start: HCC organoids were first successfully established in research in 2017 (Huch et al., Nature, 2017), and liver tumor organoids are now among the best-characterized of any cancer type. Published research has shown that HCC organoids can predict sensitivity to sorafenib, lenvatinib, and regorafenib with strong concordance to how patients actually responded to those drugs in the clinic.

Growing HCC organoids requires specialized culture media that includes liver-specific growth signals — including EGF (epidermal growth factor), HGF (hepatocyte growth factor), FGF10, and R-spondin1, a Wnt pathway activator. Without this mix, liver cancer cells typically do not survive long enough to be useful. In expert hands, organoids can be successfully established from core needle biopsy specimens about 60–75% of the time. One practical advantage: because HCC is routinely biopsied at diagnosis, the diagnostic biopsy itself can be used for organoid establishment — no separate procedure is needed, provided the laboratory receives fresh tissue immediately. Some centers are also growing HCC organoids together with immune cells, which may eventually help predict immunotherapy responses. AFP (alpha-fetoprotein) secreted by the organoids can be compared to your blood AFP level as a biological quality check confirming the culture is genuinely your tumor.

Zebrafish avatars

Turnaround: approximately 2–3 weeks | Speed advantage significant for advanced HCC

In the zebrafish avatar approach, your tumor cells are implanted into zebrafish embryos, which are then exposed to candidate drugs. Zebrafish embryos are nearly transparent, so researchers can watch in real time whether the cancer cells are growing or shrinking. For HCC, the speed advantage is particularly relevant: patients with BCLC-C (advanced) liver cancer often have rapidly progressing disease, and a 2–3 week turnaround is considerably faster than organoid systems. Zebrafish are also inexpensive enough to test several drugs or combinations in parallel. The limitation is that a zebrafish is not a human liver — the tumor microenvironment, immune context, and cirrhotic background that shape HCC behavior are not replicated. Results from zebrafish testing should be interpreted as directional signals, not clinical predictions.

CAM assay (chorioallantoic membrane)

Turnaround: approximately 1–2 weeks | Least developed clinically

The CAM assay uses the membrane of a fertilized chicken egg as a host for tumor cells. It is fast and inexpensive, and it has a blood vessel network that allows researchers to study how tumors recruit new blood vessels — a process called angiogenesis that is central to how HCC grows and how drugs like bevacizumab and sorafenib work. However, CAM assays are not widely available outside specialized research laboratories, and published clinical validation data for HCC specifically remain limited. This method is mentioned here for completeness; it is not something most patients will encounter outside a clinical trial setting.

Patient-derived xenografts (PDX)

Turnaround: 4–8 months | Most biologically complex; rarely used in real-time treatment decisions

PDX models involve implanting your tumor tissue into immunocompromised mice, allowing it to grow, and then testing drugs on the living tumor. For HCC, establishment success rates from biopsy material run roughly 40–60%, which is lower than for some other cancer types — partly because liver tumors depend heavily on their hepatic environment, which is difficult to reproduce in a mouse. The cirrhotic tissue surrounding HCC tumors also tends not to engraft well, meaning the stromal context of the original tumor is partially lost. PDX models take months to establish, making them impractical for guiding near-term treatment decisions. Their main current role in HCC is in pre-clinical drug discovery and in biobanking tumor tissue for future research, not in directing your next line of therapy.

How tissue is collected

For most HCC patients, tissue collection for functional testing can be coordinated with a procedure that is already part of your care. Core needle biopsy — where a needle is guided by ultrasound or CT into the liver tumor — is the standard method for confirming an HCC diagnosis when imaging alone is not sufficient. This same biopsy can yield enough tissue for organoid establishment, typically 2–3 needle passes of at least 1 cm in length, provided the specimen is placed immediately into specialized transport media and delivered to the laboratory within a few hours. Timing matters: room-temperature delays of more than 4–6 hours significantly reduce organoid establishment rates.

There are real complications to consider for liver cancer specifically. Many HCC patients have underlying cirrhosis, which causes two problems. First, cirrhosis reduces the blood's clotting ability (coagulopathy) and often lowers platelet counts (thrombocytopenia), which raises the bleeding risk of any biopsy. Your hepatologist and interventional radiologist will assess your INR, platelet count, and tumor location before recommending a biopsy. Second, cirrhotic liver tissue can be difficult to distinguish from tumor tissue at the time of biopsy, and contamination of the organoid culture with non-cancerous hepatocytes can reduce the quality of the results. For patients whose HCC diagnosis was confirmed by imaging alone — which is permitted by guidelines when imaging features are classic — a separate biopsy solely for functional testing would carry additional risk that needs to be explicitly discussed with your team.

For patients undergoing surgical resection, a small portion of the resected specimen can be reserved for organoid establishment — this is the highest-quality tissue option and avoids any separate biopsy risk entirely.

Timing is critical — and easy to miss: If you are interested in functional testing, you need to raise this with your oncology team before your biopsy or surgery is scheduled. Organoid establishment requires fresh tissue placed into specialized transport media within hours of collection. Once tissue has been fixed in formalin for standard pathology, or frozen without the right protocol, it cannot be used. A conversation after the procedure is too late. Ask specifically: "If I want fresh tissue preserved for organoid testing, what do I need to arrange in advance, and with whom?"

Questions to ask your oncology team

Is there a functional tumor testing program at this center, or a partner laboratory you work with for HCC organoids?
My biopsy is already scheduled — is it still possible to arrange fresh tissue preservation, or has that window passed?
Given my platelet count and liver function, what is my actual bleeding risk from a biopsy, and does it change the calculation on whether functional testing makes sense for me?
If I am heading toward resection, can a portion of the surgical specimen be sent fresh for organoid establishment?
Which drugs would you test in the organoid panel — would atezolizumab plus bevacizumab be included, or is that combination difficult to test outside an immune co-culture system?
If the organoid result conflicts with what your clinical judgment recommends, how would you weigh those two pieces of information?
Are there any clinical trials at this center using HCC organoids or functional testing as part of treatment selection that I might be eligible for?
How long would organoid results take, and would that delay be acceptable given my disease trajectory?

Selecting a center

Functional tumor testing for HCC is most accessible at large academic medical centers with dedicated liver cancer programs and existing research infrastructure. The list below reflects centers with published HCC organoid research, active clinical liver cancer programs, or strong hepatology expertise. It is not exhaustive, and availability of testing may change. Always confirm current offerings directly with each center.

Institution	Location	Known focus	How to inquire
Huntsman Cancer Institute, University of Utah	Salt Lake City, UT	Multidisciplinary liver tumor board; liver transplant program; hepatology and HCC clinical trials; Mountain West regional referral center	Call the HCI Cancer Learning Center: 1-888-424-2100; ask for a liver cancer (hepatology oncology) consultation
Memorial Sloan Kettering Cancer Center	New York, NY	HCC organoid program; published HCC functional testing research; hepatobiliary surgery and liver transplant oncology	mskcc.org/cancer-care/types/liver — request an appointment through their liver cancer service
MD Anderson Cancer Center	Houston, TX	Gastrointestinal medical oncology with active HCC clinical trials; large HCC patient volume; translational liver cancer research	mdanderson.org — Hepatobiliary Cancer Center; call 1-877-632-6789
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore, MD	HCC organoid research and liver tumor biology; liver transplant and hepatocellular carcinoma program	hopkinsmedicine.org/kimmel-cancer-center — Liver Cancer Program
UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco, CA	HCC translational research; liver transplant oncology; clinical trials in atezolizumab combinations for HCC	cancer.ucsf.edu — Liver Cancer Program; 415-353-2318
Mayo Clinic Comprehensive Cancer Center	Rochester, MN (also Scottsdale, AZ and Jacksonville, FL)	Liver cancer multidisciplinary team; liver transplant and HCC ablation expertise; research collaborations in HCC biomarkers	mayoclinic.org — request a liver cancer appointment; 1-800-512-7100

Limitations and honest caveats

Establishment is not guaranteed. Even at experienced centers, HCC organoids cannot be grown from every biopsy sample. Approximately 25–40% of attempts fail, most often because of tissue quality, delays in transport, or low tumor cell content in the biopsy. If the first attempt fails, there may not be an easy opportunity to try again.
The cirrhotic microenvironment is not replicated. HCC almost always grows inside a damaged, fibrotic liver populated by activated stellate cells, altered immune cells, and abnormal blood vessels. Current organoid and avatar systems capture the tumor cell biology reasonably well but do not fully reconstruct this surrounding environment. A drug that kills organoid cells in a dish may behave differently against a tumor embedded in scar tissue with altered blood supply.
Immunotherapy combinations are difficult to test ex vivo. Atezolizumab plus bevacizumab — the current first-line standard — works largely by activating the immune system against the tumor. Growing organoids without immune cells cannot capture this mechanism. Immune co-culture systems that include T cells or NK cells alongside HCC organoids are in early research and are not yet clinically validated.
Prospective clinical validation is limited. Published studies have shown that HCC organoid drug sensitivity correlates with patient outcomes, but most of these studies are retrospective — they looked backward at patients who had already been treated. Large prospective trials randomizing patients based on organoid results have not yet been completed for HCC, so we do not yet know with certainty whether using organoid data to select therapy improves survival compared to standard clinical decision-making.
Insurance coverage is not established. Functional tumor testing is not covered by standard insurance for HCC at this time. Out-of-pocket costs can be substantial. Some academic centers may offer access through clinical trial enrollment at no cost to the patient.
Results take time that not everyone has. A 4–8 week organoid turnaround can be acceptable for patients with early-stage disease who are considering systemic therapy options down the line, but for patients with rapidly progressive BCLC-C disease, waiting for organoid results before starting treatment may not be advisable. This is a conversation to have explicitly with your oncologist.

Key terms

Organoid: A small three-dimensional cluster of cancer cells grown in the laboratory from a patient's own tumor tissue. Organoids preserve many of the biological characteristics of the original tumor and can be used to test drug responses.
BCLC staging: The Barcelona Clinic Liver Cancer staging system, which classifies HCC from stage 0 (very early) to stage D (end-stage) based on tumor size, liver function, and performance status. It guides which treatments are recommended at each stage.
Cirrhosis: Severe scarring of the liver caused by long-term damage from hepatitis, alcohol, or fatty liver disease. Most HCC in the United States arises in a cirrhotic liver, and cirrhosis affects bleeding risk, liver function, and treatment options.
AFP (alpha-fetoprotein): A protein produced by some HCC tumors and measurable in the blood. AFP levels are used in diagnosis, as a tumor marker during treatment, and — in the organoid setting — as a way to confirm that cultured cells are genuinely from the patient's tumor.
Tumor microenvironment: The collection of non-cancer cells, blood vessels, immune cells, and structural proteins that surround and interact with tumor cells. In HCC, the cirrhotic liver creates a unique microenvironment that influences how the tumor grows and responds to treatment.
Hepatocyte growth factor (HGF): A protein that promotes liver cell survival and growth. HGF is one of the key ingredients required in organoid culture media for HCC, because liver cancer cells depend on this signal to survive outside the body.
Co-culture system: A laboratory setup in which two or more cell types are grown together — for example, tumor organoids grown alongside immune cells. Co-culture systems for HCC are being developed to study immunotherapy responses, but they are currently research tools, not clinical tests.
Patient-derived xenograft (PDX): A laboratory model in which a patient's tumor tissue is implanted and grown inside an immunocompromised mouse. PDX models take several months to establish and are used primarily in drug discovery research rather than to guide individual treatment decisions.

This appendix is provided for educational purposes only and does not constitute medical advice. Functional tumor testing approaches described here are investigational and are not currently standard of care for hepatocellular carcinoma. Clinical evidence, institutional availability, and insurance coverage for these methods are evolving. Always discuss treatment decisions, biopsy procedures, and experimental options with your hepatologist, oncologist, and transplant team, who can evaluate your individual liver function, tumor stage, and overall health. Information in this appendix reflects published research and clinical practice as of mid-2026; specific programs and availability may have changed.